Check for updates

OPEN ACCESS

EDITED BY Balaji Govindaswami, Frontiers Media SA, Switzerland

REVIEWED BY Sharon Casavant, University of Connecticut, United States Kiyotaka Nemoto, University of Tsukuba, Japan

*CORRESPONDENCE Zhangbin Yu ⊠ yuzhangbin@126.com Jun Chen ⊠ 75chj@163.com

[†]These authors have contributed equally to this work and share last authorship

RECEIVED 15 March 2024 ACCEPTED 08 November 2024 PUBLISHED 21 November 2024

CITATION

Zhang R, Ying E, Wu X, Qin H, Guo Y, Guo X, Yu Z and Chen J (2024) A systematic review and meta-analysis of breastfeeding and neurodevelopmental outcomes in preterm infant. *Front. Public Health* 12:1401250. doi: 10.3389/fpubh.2024.1401250

COPYRIGHT

© 2024 Zhang, Ying, Wu, Qin, Guo, Guo, Yu and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

A systematic review and meta-analysis of breastfeeding and neurodevelopmental outcomes in preterm infant

Ruolin Zhang¹, Erya Ying¹, Xiujuan Wu¹, Han Qin¹, Yanping Guo², Xin Guo³, Zhangbin Yu^{4*†} and Jun Chen^{1*†}

¹Department of Neonatology, Nanshan Maternity & Child Healthcare Hospital, Shenzhen, Guangdong, China, ²Department of Pediatrics, Peking University Shenzhen Hospital, Shenzhen, Guangdong, China, ³Department of Neonatology, Longgang District Maternity & Child Healthcare Hospital of Shenzhen City, Longgang Maternity and Child Institute of Shantou University Medical College, Shenzhen, China, ⁴Department of Neonatology, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, China

Background: Prematurity significantly impacts neonatal health worldwide, necessitating effective interventions to improve outcomes for these vulnerable infants. While breastfeeding has emerged as a cornerstone of preterm care, its precise impact on neurodevelopment remains a subject of ongoing inquiry and debate. This systematic review aims to investigate the existing evidence in this area.

Methods: On December 17, 2023, online databases including PubMed, The Cochrane Library, Embase, Web of Science, CNKI, VIP, CBM, and Wan Fang Data were searched. Comparisons were classified into several categories: never breastfeeding (Never-BF) versus exclusive breastfeeding, Never-BF versus any breastfeeding (Any-BF), predominant preterm formula (Pre-PTF) versus predominant breastfeeding (Pre-BF), and Pre-PTF versus predominant donor breast milk (Pre-DBM) groups. Randomized controlled trials and observational studies were analyzed separately through meta-analyses. Each study's risk of bias was assessed, and the GRADE system was utilized to evaluate the certainty of the findings.

Results: Sixteen studies met the inclusion criteria, comprising one RCT and 15 cohort studies. The key findings indicated that infants in the Any-BF groups demonstrated superior long-term cognitive scores compared to those in the Never-BF groups, particularly evident in infants assessed before 18 months in the Pre-BF groups versus Pre-PTF groups. A reduced risk of neurodevelopmental impairment was also observed in preterm infants in the Any-BF groups. Evidence regarding the effect of breastfeeding on motor development was inconclusive, except for potential motor improvement in extremely low birth weight infants in the Any-BF groups. Neither exclusive breastfeeding nor pre-DBM exhibited clear superiority over Pre-PTF in terms of neurodevelopmental outcomes for preterm infants. Caution is warranted due to potential publication bias impacting the assessment of breastfeeding's impact on motor skills.

Conclusion: Our systematic review supports current recommendations for breastfeeding in preterm infants, emphasizing its positive effects on cognitive abilities and reduced risk of neurodevelopmental disorders. Further studies are needed to clarify if DHM provides neurodevelopmental benefits comparable to maternal milk, as current evidence does not sufficiently address this question. Additionally, future investigations should prioritize refining our understanding of the influence of breastfeeding on motor development in this vulnerable population.

Systematic review registration: PROSPERO, identifier CRD42023492274, Available at: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023492274.

KEYWORDS

preterm infant, breastfeeding, neurodevelopmental outcomes, cognitive, motor, neurodevelopmental impairment

1 Introduction

In 2020, approximately 13.4 million live births were premature, affecting almost 9.9% of global live births (1). This figure represents a staggering public health burden, as nearly 900,000 neonatal deaths result from direct complications of premature birth annually (2). Recent global data suggests that preterm births remain a pressing issue in countries like China, which contributes significantly to global numbers with 6.1% of its births being preterm, totaling more than three quarters of a million (3). Premature birth is not just an issue of early survival but one of long-term developmental health, contributing to neonatal mortality, as well as long-term adverse outcomes such as neurodevelopmental impairments, chronic diseases, and considerable economic costs (2–7). Given their vulnerability, preterm infants require special attention and intensified care (8). Among the most effective interventions available is breastfeeding.

Breastfeeding emerges as a crucial intervention for premature infants, providing well-established protection against complications associated with prematurity (8–10). It has a positive impact on both short-term and long-term outcomes, particularly in terms of neurodevelopment (11). The World Health Organization (WHO) and other international health organizations advocate for exclusive breastfeeding for the first 6 months of life, followed by continued breastfeeding alongside appropriate complementary feeding throughout the second year (12, 13). Additionally, China's 2018 guidelines on Breastfeeding Promotion Strategies align with WHO recommendations, emphasizing the initiation of breastfeeding within the initial 30 min post-birth (14).

Breastfeeding confers protection against common diseases such as gastrointestinal tract infection, atopic eczema, respiratory infections, and otitis media (8). It also mitigates the risk of type 2 diabetes and childhood overweight/obesity (15). Furthermore, breastfeeding promotes cognitive (16-18) and motor skill (19, 20) development, which are critical indicators of neurodevelopmental outcomes (NDOs) in early life. Moreover, numerous studies show that breastfed children have higher verbal intelligence and, in boys, higher intelligence quotient (IQ) scores, total brain volume and white matter volume at 12 to 18 years of age, suggesting that the beneficial effects of breastfeeding continue from the NICU to adolescence (21-23). Evidently, breastfeeding positively influences the future health of the child, resulting in reduced healthcare burdens for health systems. However, despite international recommendations and documented benefits, global rates of exclusive breastfeeding for at least 6 months remain low at 40% (10, 24), and in China at 47.9% (25, 26), contrasting with WHO's suggestions.

While ample evidence supports the association between breastfeeding and improved medical outcomes (27–29), whether breastfeeding exerts a lasting impact on children's NDOs remains a contentious issue (30, 31). Several studies indicate a positive association between breastfeeding and NDOs (32–34). However, critics argue that enhanced NDOs are more closely linked to maternal education, socioeconomic status, IQ, and sensitivity rather than the nutrients in breast milk (35, 36). Thus, it is crucial to systematically review evidence both supporting and opposing the hypothesis that breastfeeding reduces the risk of suboptimal NDOs and determine if there is an independent reproducible effect of breastfeeding on NDOs in preterm infants. This systematic review and meta-analysis aim to synthesize the available evidence.

2 Materials and methods

2.1 Registration

Our systematic review and meta-analysis followed the PRISMA criteria (37) (Supplementary Table S1) and MOOSE guidelines (38) (Supplementary Table S2). Registration details for this review are documented in PROSPERO, the international prospective register of systematic reviews (Registration ID: CRD42023492274).

2.2 Criteria for selected studies for this review

This meta-analysis systematically assessed global studies exploring the correlation between breastfeeding and NDOs in preterm infants.

2.2.1 Included studies met the following criteria

- a) Participants: Preterm infants (gestational age < 37 weeks);
- b) Interventions: Provision of breastfeeding during the infants' hospital stay;
- c) Comparisons: Evaluation of different feeding strategies (including exclusive, any, and never breastfeeding) and varying doses of breastfeeding administration;
- d) Outcomes: NDOs. The primary outcome was cognitive scores measured in preterm infants at follow-up using validated assessment tools. Secondary outcomes included neurodevelopmental scores related to language and motor domains and the incidence of neurodevelopmental impairment (NDI), defined as the presence of one or more of the following: Bayley Scales of Infant Development (BSID-II/III) cognitive or motor scores below 70, Kaufman Assessment Battery for Children (KABC) mental processing scores below 85, blindness, deafness requiring hearing aids or cochlear implants, or cerebral palsy;
- e) Study design: Randomized controlled trials (RCTs) and observational cohort studies, both prospective and retrospective.

2.2.2 Exclusion criteria were applied in the following cases

- a) Inclusion of term neonates;
- b) Studies involving the same participants but with different aims;
- c) Restriction of reported outcomes to behavioral/temperamental assessments or isolated motor skills, which are of uncertain value as prognosticators of long-term neurodevelopment or cognitive function;
- d) Ineligible publication types, such as meta-analyses, systematic reviews, editorials, commentaries, guidelines, pilot studies, or case reports;
- e) Failure to meet the designed inclusion criteria.

2.3 Intervention protocol

The intervention compared the effects of various breastfeedingrelated feeding strategies. The comparison groups were categorized as follows:

- a) Never Breastfeeding (Never-BF) versus Exclusive Breastfeeding (Exclusively BF);
- b) Never-BF versus Any Breastfeeding (Any-BF);
- c) Predominant Preterm Formula (Pre-PTF) versus Predominant Breastfeeding (Pre-BF);
- d) Pre-PTF versus Predominant Donor Breast Milk (Pre-DBM).

2.4 Search strategy

Two researchers (RZ, EY) conducted a comprehensive search across databases, including PubMed, The Cochrane Library, Embase, Web of Science, CNKI, VIP, CBM, and Wan Fang Data, on December 17, 2023. Publications before January 2000 were excluded to ensure that the findings reflect current knowledge. The search was limited to studies published in English or Chinese. Additional references were sourced from cited literature. The search terms included "breast milk," "human milk," "breastfeeding," and relevant MeSH terms, with neonate limiters specific to each database. Detailed search strategies are available in the Supplementary Table S3.

2.5 Literature retrieval and data extraction

Data extraction was performed by two independent authors (RZ, EY) using predesigned forms. In case of disagreement, a third author (XW) mediated discussions to reach a consensus. Extracted information included study details (authorship, publication year, location), population characteristics (sample size, gestational age, birth weight), and intervention, comparison, and outcomes.

2.6 Methodological quality evaluation

The Risk of Bias (RoB) tool from the Cochrane Collaboration was used to evaluate bias in RCTs. This tool consists of six domains: randomization method, allocation concealment, blinding, handling of incomplete outcome data, selective reporting, and other sources of bias (39). Additionally, the Newcastle-Ottawa Scale (NOS) (40) was used to assess and assign scores for the quality of cohort studies. The NOS assesses sample selection, cohort comparability, and outcome assessment. Sample selection is evaluated based on four criteria: the representativeness of the exposed cohort, the selection of the non-exposed cohort, the ascertainment of exposure, and the demonstration that the outcome of interest was absent at the study's start. Cohort comparability, either through design or analysis, is also essential. Additionally, it is important to address factors such as outcome assessment, adequate follow-up for outcomes, and cohort follow-up adequacy. Quality assessment was conducted independently by two researchers (YG and XG), with any discrepancies resolved through arbitration by a third researcher (HQ) in cases of disagreement.

2.7 Statistical analysis

A meta-analysis was conducted to determine the correlation between breastfeeding and NDOs. Dichotomous outcomes were reported as relative risks (RR) with 95% confidence intervals (CI), while continuous variables were presented as standard mean differences (SMD) with corresponding 95% CI and underwent statistical analysis. The I^2 statistic was used to assess heterogeneity, categorized as not important (0 to 30%), moderate (30 to 50%), substantial (50 to 75%), or considerable (75 to 100%) (39), with corresponding *p*-values considered. If heterogeneity was present (p < 0.10 or $P \ge 50\%$), a random-effects model was used.

For studies reporting multiple statistical models, priority was given to the most adjusted one. When multiple studies provided data from the same sample, preference was accorded to the one with the most detailed results or the largest sample size. In cases of diverse neurodevelopmental assessment points, precedence was given to measurements the latest one.

The included studies, primarily prospective or retrospective observational studies, may present significant clinical or methodological variability. To address this, sensitivity analysis was conducted by removing one study at a time to evaluate its effect on the pooled SMD. Subgroup analyses were performed based on infants' age at assessment (categorized as <18 months, 18–24 months, and >24 months), gestational age (GA) and birth weight (BW) (GA <32 weeks and/or BW <1,500 g, and GA <28 weeks and/or BW <1,000 g), given the variability in GA and BW among the studies. Additional subgroup analyses considered whether studies adjusted for key confounders affecting NDOs, at least maternal education or IQ of covariates. To detect potential publication bias and the effect of small study sizes, funnel plots and Egger's test were utilized (41). All statistical analyses were performed using RevMan 5.4.1 and Stata MP version 17.0 (Stata Corporation, College Station, TX).

2.8 Summary of findings and GRADE table

The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework and GRADEPro guideline development tool software was used to create outcome-specific summary tables. These tables evaluated the quality of evidence, effect consistency, imprecision, indirectness, and publication bias for each outcome (42). High-quality evidence is considered to be RCTs with no limitations, while observational studies are considered to provide low-quality evidence. Studies can be downgraded by one (for serious concern) or two (for very serious concerns) based on the risk of bias, inconsistency, indirectness, imprecision, and publication bias. Observational studies with a large effect size have been upgraded by one for a strong association (43). For each outcome, we report our certainty in the findings as very low, low, moderate, or high, separately according to the study design (randomized controlled trials, observational studies).

3 Results

3.1 Literature screening process

Systematically searching databases such as PubMed, The Cochrane Library, Embase, Web of Science, CNKI, VIP, CBM, and Wan Fang Data, a total of 3,190 studies were identified. Following the removal of 461 duplicates, the titles, and abstracts of the remaining 2,729 articles were reviewed. Employing predetermined criteria, 2,672 articles were excluded as they did not meet the inclusion criteria. After a thorough examination of the complete text, 41 articles were excluded for various reasons. Finally, 16 original studies were selected that met

the criteria for systematic review and meta-analysis to ensure the reliability of the results. The retrieval procedures are illustrated in Figure 1 of the PRISMA flow chart (37).

The review examined data from 2000 to 2023, including 1 RCT and 15 cohort studies (66.7% prospective, 33.3% retrospective) from 8 different countries: Australia, Canada, Chile, Israel, Japan, Kenya, the UK, and the United States. For further details, please consult Table 1. Out of the selected studies (31, 36, 44–57), 14 were metaanalyzed (36, 44, 46–57), while 2 were synthesized narratively (31, 45) due to specific methodological differences or unavailable data for quantitative synthesis.

The study analyzed 16 selected studies conducted between 1996 and 2015, involving 3,982 preterm babies with sample sizes ranging from 18 to 1,035 participants. Seven studies (31, 36, 44, 48, 49, 51, 54) included infants born <32 weeks GA and/or <1,500 g BW (n=1,444). Additionally, four studies (45, 46, 52, 56) targeted infants born <28 weeks' GA and/or with a BW <1,000 g (n=1,321). Five of the studies (47, 50, 53, 55, 57) focused on infants born <37 weeks' GA and/or with a total of 1,199 participants. The studies analyzed in this research were conducted on preterm infants with varying GA and BW, and none of the study reported results stratified by GA and BW. Table 1 provides details of the included studies.



Reference	Region	Study design	Enrolled duration	Sample size (<i>n</i>)	Inclusion criteria	Neurologic assessment	Outcomes	Assessment point	Adjustment for
Belfort et al. (2016) (31)	Australia	Prospective cohort study	2001 to 2003	180	GA < 30 wks., BW <1,250 g	BSID-II, MRI	MDI, PDI, IQ, brain volumes	24 months, 7 years	Maternal characteristics: age, education level, marital status, occupation, socioeconomic status, language. Neonatal characteristics: GA, gender, exposure to antenatal or postnatal corticosteroids, BPD ($O_2 @ 36$ wk), NEC, sepsis
Bier et al. (2002) (57)	USA	Prospective cohort study	1996 to 1999	39	BW<2,000g	BSID-II, AIMS	MDI, Motor development	3 months, 7 months, 12 months	Maternal characteristics: maternal PPVT score; Neonatal characteristics: No. of days of oxygen
Colacci et al. (2017) (56)	USA	Retrospective cohort study	2011 to 2013	85	GA < 37 wks., BW < 1,000 g	BSID-III	MDI, language, PDI, NDI	6 months, 12 months, 18 months	Maternal characteristics: education level, family income; Neonatal characteristics: GA, BPD, IVH, NEC, SAG
Feldman et al. (2003) (55)	Israel	Prospective cohort study	1996 to 1999	86	GA<33 wks., BW<1,750 g	BSID-II	PDI, MDI	6 months	Maternal characteristics: age, education level, marital status, socioeconomic status; Neonatal characteristics: GA, BW, the degree of medical risk, multiple births, apnea
Furman et al. (2004) (36)	USA	Prospective cohort study	1997 to 1999	119	GA < 33wk., BW 600–1,499 g	BSID-II, The Amiel-Tison	PDI, MDI, NDI	20 months	Maternal characteristics: education level, marital status, ethnicity. Neonatal characteristics: apnea, BPD (O2 @ 28 d), IVH, jaundice, NEC, PVL, sepsis
Hair et al. (2022) (54)	USA, Australia	Retrospective cohort study	2006 to 2010	252	BW ≤1,250 g	BSID-III	MDI, language, PDI	18–22 months	Neonatal characteristics: BW, gender, NEC, center
Jacobi- Polishook et al. (2016) (53)	Australia	Prospective cohort study	2001 to 2005	611	GA≤33 wks.	BSID-II	PDI, MDI	18 months	Maternal characteristics: age, education level, smoking status during pregnancy, number of children and adults living at home, occupation, Home Screening Questionnaire score; Neonatal characteristics: GA, BW, gender, exposure to antenatal or postnatal corticosteroids, CRIB, IVH (3 to 4), NEC, ROP
Madore et al. (2017) (52)	USA	Prospective cohort study	2009 to 2012	81	BW < 1,000 g	BSID-III	MDI, language, PDI	12 months, 24 months	Maternal characteristics: social work involvement; Neonatal characteristics: multiple births, BPD
O'Connor et al. (2003) (50)	UK, USA, Chile	Retrospective cohort study	1996 to 1998	463	GA < 33wk., BW 750–1,800 g	BSID-II	PDI, MDI	12 months	Maternal characteristics: HOME Inventory, the vocabulary subtest of the maternal WAIS-R, smoking status during pregnancy and in-home; Neonatal characteristics: GA, SAG

(Continued)

10.3389/fpubh.2024.1401250

Zhang et al.

TABLE 1 (Continued)

Reference	Region	Study design	Enrolled duration	Sample size (n)	Inclusion criteria	Neurologic assessment	Outcomes	Assessment point	Adjustment for
O'Connor et al.	Canada	RCT	2010 to 2012	363	BW<1,500g	BSID-III	MDI, language,	18 months	Maternal characteristics: education level;
(2016) (51)							PDI		Neonatal characteristics: BW, dose of mother's milk
Patra et al.	USA	Retrospective cohort	2008 to 2012	251	BW < 1,500 g	BSID-III	MDI, language,	20 months	Maternal characteristics: education level, race/
(2017) (49)		study					PDI		ethnicity;
									Neonatal characteristics: GA, gender, multiple births,
									apnea, BPD, NEC, SAG, sepsis, severe brain injury
Pinelli et al.	Canada	Prospective cohort	NR	148	BW <1,500 g	BSID-II	MDI, PDI	6 months, 12 months	Maternal characteristics: age, socioeconomic status;
(2003) (48)		study							Neonatal characteristics: BW, dose of mother's milk
Tanaka et al.	Japan	Prospective cohort	1999 to 2000	18	NR	KABC	MPC	5 years	NR
(2009) (47)		study							
Vohr et al.	USA	Prospective cohort	1999 to 2001	1,035	BW < 1,000 g	BSID-II The	MDI, PDI, NDI	18-22 months	Maternal characteristics: age, education level, marital
(2006) (46)		study				Amiel-Tison			status, race, ethnicity;
									Neonatal characteristics: GA, gender, BPD (O ₂ @ 36
									wk), IVH (3 to 4), NEC, PVL, SAG, sepsis
Were et al.	Kenya	Prospective cohort	In 2002	120	BW < 1,000 g	Dorothy Egan's	Developmental	24 months	NR
(2006) (45)						Model, Saigaland	delay,		
						Rosenbaum's	Functional		
						method	disability		
Yackobovitch-	Israel	Retrospective cohort	2013 to 2015	131	GA < 32 wks.	The Griffiths	Locomotors;	12 months	Maternal characteristics: age, education level,
Gavan et al.		study				Mental	personal-social;		socioeconomic status, type of pregnancy;
(2023) (44)						Development	hearing and		Neonatal characteristics: GA, BW Z-score, gender,
						Scales	language; eye		exposure to antenatal corticosteroids, multiple
							and hand co-		births, birth head circumference Z-score, apnea,
							ordination and		mechanical ventilation
							performance		

AIMS, The Alberta Infant Motor Scale; BSID, Bayley Scales of Infant Development; BF, breastfeeding; BPD, bronchopulmonary dysplasia; BW, birth weight; d, days; CLD, chronic lung disease; CRIB, clinical risk index for babies score; GA, gestational age; IVH, intraventricular hemorrhage; KABC, The Kaufman Assessment Battery for Children; MDI, The Mental Development Index; MPCs, The Mental Processing Composite Scale; NDI, neurodevelop-mental impairment; NR, not reported; PDI, The Psychomotor Development Index; PPVT, the peabody picture vocabulary test score; PVL, periventricular leukomalacia; ROP, retinopathy of prematurity; RCT, randomized control trial; SAG, small for gestational age; WAIS-R, The Revised Wechsler Adult Intel-ligence Scale; wks., weeks.

The studies by Were et al. (45) provided evidence for directly evaluating the advantages of Never-BF (where formula constituted the entire diet) versus exclusive BF (where breastfeeding constituted the entire diet, comprising mother's own milk or DBM). Five articles (36, 44, 46, 53, 57) which included Never-BF, with exclusive BF or a combination of breastfeeding and formula. Eleven articles (31, 36, 47–50, 52–56) examined the effects of Pre-PTF, including low breastfeeding dose combined with preterm formula, compared to Pre-BF, including exclusive BF or predominant dose of breastfeeding combined with preterm formula. Three studies (51, 52, 54) provided DBM in either the intervention or control groups. The intervention in each study is described in detail in Table 2.

3.2 Evaluation of bias in included studies

The examination of potential bias in RCT articles indicates a low risk, which can be ascribed to the proper implementation of randomization and blinding protocols. This ensures the objectivity of outcomes, thereby reducing the likelihood of bias. The evaluation of bias in cohort studies was conducted using the Newcastle-Ottawa Quality Assessment Scale (NOS), yielding scores ranging from 6 to 9 stars (Table 2). Eleven of them had a score of no less than 7, indicating that they were extremely high-quality studies with a low risk of bias. Further details on each item are provided in Supplementary Table S4.

3.3 Outcome assessment

The assessment periods varied from 6 months to 7 years. Most studies evaluated developmental outcomes during early childhood, specifically between 18 to 24 months (36, 45, 46, 49, 51–54, 56); however, five studies assessed outcomes prior to 18 months (44, 48, 50, 55, 57). In contrast, only two articles examined NDOs beyond 24 months to evaluate the long-term effects of NDOs in preterm infants (31, 47). For instance, Tanaka et al. investigated the association between breastfeeding—particularly the resulting DHA levels in the red blood cell membranes of infants—and the cognitive function of very low birth weight (VLBW) infants at 5 years of age (47). Similarly, a study conducted by Belfort et al. (31) focused on the effects of predominant breastfeeding on very preterm infants, measuring brain volumes and NDOs at 7 years of age.

The BSID emerged as the most prevalent outcome measure, with eight studies employing BSID-II (31, 36, 46, 48, 50, 53, 55, 57) and five utilizing BSID-III (49, 51, 52, 54, 56). Other assessments encompassed various developmental tests, including the Amiel-Tison (36, 46), the Kaufman Assessment Battery for Children (KABC) (47), the Alberta Infant Motor Scale (AIMs) (57), the Griffiths Development Scales (GMDS) (44), and assessments based on Dorothy Egan's Model and Saigaland Rosenbaum's method (45). In addition, the infants underwent the standard neurologic examinations listed in Table 1.

3.4 Never breastfeeding versus exclusive breastfeeding (*n* = 1)

Only one study, conducted by Were et al. (45), a prospective cohort investigation, focuses on the impact of exclusive BF on preterm infants

born in Kenya weighing between 1,000 g and 1,500 g. The findings of this study indicate that neonates exclusively breastfed exhibit notably elevated rates of disability compared to those never exposed to breastfeeding at the age of 2 years (RR 2.04, 95% CI 1.1, 3.78, p=0.02). However, it is imperative to underscore that the logistic regression analysis failed to ascertain early feeding as an independent prognosticator of functional disability. Additionally, the potential influence of confounding factors, such as maternal health and socio-economic status, was not controlled for, which may have affected the reliability of the study results.

Overall, this inquiry does not definitively demonstrate the superiority of Exclusively BF over Never-BF in improving the long-term NDOs of preterm infants.

3.5 Never breastfeeding versus any breastfeeding (n = 5)

Five cohort studies (36, 44, 46, 53, 57) have explored the impact of Never-BF versus Any-BF on NDOs in preterm infants born before 33 weeks' gestation. Notably, four studies (36, 46, 53, 57) utilized the BSID-II assessment to evaluate cognition and motor at various ages (7, 12, 18, or 20 months), while 1 study employed the GMDS (44) to evaluate mental development at 12 months.

3.5.1 Cognitive scores

Yackobovitch-Gavan et al. (44) reported that Any-BF in the first month was associated with a 6–7-point increase in GMDS scores at 12 months corrected age, adjusted for maternal factors, such as maternal age, education level, and socioeconomic status. Each 50 mL/ kg/day increase in breastfeeding volume corresponded to a 2–3 point increase in GMDS scores (p < 0.01).

Four studies (36, 46, 53, 57) included in the meta-analysis found Any-BF associated with higher cognitive scores compared to Never-BF in a fixed effects model (SMD -0.19, 95% CI -0.31, -0.07, p=0.002, Figure 2; very low certainty evidence; 4 observation studies, 1,783 participants, Supplementary Table S7), with non-significant evidence of heterogeneity (I^2 =44%, p=0.15).

3.5.2 Motor scores

Five studies (36, 44, 46, 53, 57) contributed motor scores to the meta-analysis but failed to detect differences in motor development outcomes (SMD -0.08, 95% CI -0.37, 0.21, p=0.60, Figure 2; very low certainty evidence; 5 observation studies, 1,303 participants, Supplementary Table S7), with a substantial heterogeneity in all studies (p=0.007, l^2 = 71%, Figure 2).

A random effects model and subgroup analysis revealed that infants born before 28 weeks of gestation or weighing less than 1,000 grams (SMD -0.18, 95% CI -0.04, -0.32, p = 0.01, Supplementary Table S6) and assessed prior to 18 months exhibited a slight advantage in motor scores. The observed heterogeneity may be attributed to variations in the populations studied and the differing time points at which NDOs were evaluated.

3.5.3 Incidence of neurodevelopmental impairment

Two trials (36, 46) contributed data for a meta-analysis on the incidence of NDI, indicating a potential decrease in such impairment with any breastfed infants in a fixed effects model (RR 1.17, 95% CI

Reference	Groups	Proportion of mil	k provided to the differer	nt groups	Fortifier	Comparisons for this review	Study duration	Scores of
		Formula	МОМ	DBM				NOS
Belfort et al. (2016) (31)	NA	Undefined	>50% of nutrition	NA	Y	Pre-PTF vs. Pre-BF (Synthesized narratively)	First 4 wk. of life	9
Bier et al. (2002) (57)	Gp1	170±258 mL/kg/wk.	852±429 mL/kg/wk.	N/A	Y	Never-BF vs. Any-BF (Gp1 vs. Gp2)	Duration of hospitalization	7
	Gp2	100%	N/A	N/A				
Colacci et al. (2017) (56)	Gp1	NA	92% of times	Undefined	Y	Pre-PTF vs. Pre-BF (Gp1 vs. Gp2)	First 4 wk. of life	7
	Gp2	83 (17,100) % of times	Undefined	NA				
Feldman et al. (2003) (55)	Gp1	1,404.8±602.7 mL	7,375.2±3,211.6 mL (> 75% of nutrition)	N/A	NR	Pre-PTF vs. Pre-BF (Gp1 vs. Gp2)	Duration of hospitalization	7
	Gp2	7,848.1 ± 3,668.3 mL	970.2 ± 200.0 mL (< 25% of nutrition)	N/A				
Furman et al. (2004) (36)	Gp1	Undefined	≥50 mL/kg	N/A	Y	Never-BF vs. Any-BF (Gp1+Gp2+Gp3 vs.	First 4 wk. of life	9
	Gp2	Undefined	25–49 mL/kg	N/A		Gp4), Pre-PTF vs. Pre-BF (Gp1 vs.		
	Gp3	Undefined	1-25 mL/kg	N/A		Gp2+Gp3)		
	Gp4	100%	N/A	N/A				
Hair et al. (2022) (54)	Gp1	NA	Undefined	Undefined	Y	Pre-PTF vs. Pre-BF (Gp1 vs. Gp2), Pre-	From birth to 34–36 CA	7
	Gp2	Undefined	Undefined	NA		DBM vs. Pre-PTF (Gp1 vs. Gp2)		
Jacobi-Polishook et al. (2016) (53)	Gp1	Undefined	4th quartile of BM intake	N/A	Y	Never-BF vs. Any-BF (Gp1+Gp2+Gp3+Gp4 vs. Gp5), Pre-PTF	Duration of neonatal admission	8
	Gp2	Undefined	3rd quartile of BM intake	N/A		vs. Pre-BF (Gp1+Gp2 vs. Gp3+Gp4)		
	Gp3	Undefined	2nd quartile of BM intake	N/A				
	Gp4	Undefined	1st quartile of BM intake	N/A				
	Gp5	100%	NA	N/A				
Madore et al. (2017) (52)	Gp1	NA	100%	NA	Y	Pre-PTF vs. Pre-BF (Gp1+Gp2 vs. Gp3),	First month of life	6
	Gp2	NA	Undefined	>50%		Pre-PTF vs. Pre-DBM (Gp2 vs. Gp3)		
	Gp3	>50%	Undefined	NA				
O'Connor et al. (2003) (50)	Gp1	<100 mL/kg	>80%	N/A	Partial	Pre-PTF vs. Pre-BF (Gp1+Gp2 vs.	From initiation of enteral feeding	6
	Gp2	Undefined	≥50%	N/A		Gp3+Gp4)	to Term CA or hospital discharge	
	Gp3	Undefined	<50%	N/A				
	Gp4	>80%	<100 mL/kg	N/A				

Frontiers in Public Health

(Continued)

10.3389/fpubh.2024.1401250

Reference	Groups	Proportion of mil	k provided to the differer	nt groups	Fortifier	Comparisons for this review	Study duration	Scores of
		Formula	МОМ	DBM				NOS
O'Connor et al. (2016) (51)	Gp1	N/A	58.4% (13.6-96.0%) of nutrition	Undefined	Y	Pre-PTF vs. Pre-DBM (Gp1 vs. Gp2)	From consent to 90 d of life	N/A
	Gp2	Undefined	63.3% (9.6–97.2%) of nutrition	N/A				
Patra et al. (2017) (49)	Gp1	Undefined	$132 \pm 10(5$ th quintiles of BM intake)	NA	Y	Pre-PTF vs. Pre-BF (Gp1+Gp2+Gp3 vs. Gp4+Gp5)	Duration of hospitalization	7
	Gp2	Undefined	$103 \pm 10(4$ th quintiles of BM intake)	NA	_			
	Gp3	Undefined	65±16(3rd quintiles of BM intake)	NA				
	Gp4	Undefined	21±7(2nd quintiles of BM intake)	NA				
	Gp5	Undefined	$4\pm4(1$ st quintiles of BM intake)	NA				
Pinelli et al. (2003) (48)	Gp1	Undefined	>80%	N/A	Y	Pre-PTF vs. Pre-BF (Gp1 vs. Gp2)	Duration of neonatal admission	7
	Gp2	Undefined	<80% or no	N/A				
Tanaka et al. (2009) (47)	Gp1	Undefined	>80%	N/A	NR	Pre-PTF vs. Pre-BF (Gp1 vs. Gp2)	Group allocation based on feeds	6
	Gp2	Undefined	<80%	N/A			within first month of life with outcome follow-up at 5 years	
Vohr et al. (2006) (46)	Gp1	Undefined	Ranged from 1.0 to 110.6 mL/ kg/d	N/A	Y	Never-BF vs. Any-BF (Gp1 vs. Gp2)	Duration of neonatal admission with 18-month outcome follow up	9
	Gp2	100%	N/A	N/A			for neurodevelopment	
Were et al. (2006) (45)	Gp1	NA	100%	NA	NR	Never-BF vs. Exclusive-BF (Gp1 vs. Gp2)	Duration of neonatal admission	7
	Gp2	100%	NA	NA		(Synthesized narratively)		
	Gp3	Undefined	Undefined	NA				
Yackobovitch-Gavan et al. (2023) (44)	Gp1	Undefined	134 (100, 149) mL/kg/d	NA	Y	Never-BF vs. Any-BF (Gp1 vs. Gp2)	First month of life	6
	Gp2	100%	NA	NA				

Data presented as mean ± SD or median (IQR) unless otherwise stated. BF, breastfeeding; CA, corrected Age; DBM, donor breast milk; Gp, group; NA, not applicable; NR, not reported; Pre-, predominant; wk., week; Y, yes.

	Nev	er-Bl	F	Ar	ıy-BF		5	Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mean	SD	Total	Mean	SD 1	otal	Weight	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Bier 2002	91	10	10	100	12	29	2.7%	-0.76 [-1.50, -0.02]	
Furman 2004	80	16	29	80.5	17.4	69	7.7%	-0.03 [-0.46, 0.40]	
Jacobi-Polishook 2016	95	14	46	94.5	15.3	565	16.1%	0.03 [-0.27, 0.33]	
Vohr 2006	75.8	16	260	79.9	18	775	73.5%	-0.23 [-0.37, -0.09]	
Total (95% CI)			345		1	438	100.0%	-0.19 [-0.31, -0.07]	◆
Heterogeneity: Chi ² = 5.32	2, df = 3	(P =	0.15);	l² = 44%				_	
Test for overall effect: Z =	3.07 (P	= 0.0	002)						-1 -0.5 0 0.5 1 Never-BF Any-BF
.2. Motor Scores									
	1	lever	r-BF		Any-B	F		Std. Mean Difference	Std. Mean Difference
Study or Subgroup	Mea	n S	<u>SD To</u>	tal Mea	in SE) Tot	al Weigh	t IV, Random, 95% CI	IV, Random, 95% Cl
Bier 2002	4	7	15	10 6	60 20) 2	29 14.6%	6 -0.67 [-1.41, 0.06]	
Furman 2004	8	0	16	29 72	.4 16.8	8 6	<u>59</u> 24.2%	6 0.46 [0.02, 0.89]	
Vohr 2006	81.	3	17 2	60 84	.6 19) 77	75 35.8%	6 -0.18 [-0.32, -0.04]	
Yackobovitch-Gavan 2023	94.	9 10).9	30 99	.9 13.6	5 10	01 25.4%	6 -0.38 [-0.79, 0.03]	
Total (95% CI)			3	29		97	4 100.0%	6 -0.15 [-0.51, 0.21]	
		10 6	1. df = 3	3 (P = 0.	01); l² =	: 72%			
Heterogeneity: Tau ² = 0.09	9; Chi² =	10.0	.,						
Heterogeneity: $Tau^2 = 0.05$ Test for overall effect: Z = 0	9; Chi² = 0.81 (P :	= 0.42	2)						-1 -0.5 0 0.5 1 Never-BF Anv-BF
Heterogeneity: Tau ² = 0.00 Test for overall effect: Z = 0	9; Chi² = 0.81 (P≕ D I	= 0.42	2)						Never-BF Any-BF
Heterogeneity: Tau ² = 0.05 Test for overall effect: Z = 1 3.3. Incidence of NI	9; Chi² = 0.81 (P≕ DI Nev	= 0.42	2) F	Anv	-BF			Risk Ratio	Risk Ratio
Heterogeneity: Tau ² = 0.05 Test for overall effect: Z = 1 3.3. Incidence of NI Study or Subgroup	9; Chi² = 0.81 (P DI Nev Even	er-B	2) F Fotal	Any Event	-BF s Tot	al W	/eight	Risk Ratio IV. Fixed. 95% Cl	Risk Ratio
Heterogeneity: Tau ² = 0.05 Test for overall effect: Z = 1 3.3. Incidence of NI Study or Subgroup Furman 2004	9; Chi² = 0.81 (P DI Nev Even	= 0.42	2) F <u>Fotal</u> 29	Any Event	- BF <u>s Tot</u> 5 €	<u>al W</u> 9	/eight 0.3%	Risk Ratio IV, Fixed, 95% Cl 0.95 [0.20, 4.63]	-1 -0.5 0 0.5 1 Never-BF Any-BF Risk Ratio
Heterogeneity: Tau ² = 0.05 Test for overall effect: Z = 1 3.3. Incidence of NI Study or Subgroup Furman 2004 Vohr 2006	9; Chi² = 0.81 (P ÷ DI Nev Even	rer-B ts 1 2	²⁾ F <u>F</u> 29 29 260	Any Event	7 -BF 5 6 7 77	al W	/eight 0.3%	Risk Ratio IV, Fixed, 95% Cl 0.95 [0.20, 4.63] 1 17 [1 07 1 29]	-1 -0.3 0 0.5 1 Never-BF Any-BF Risk Ratio IV, Fixed, 95% Cl
Heterogeneity: Tau ² = 0.05 Test for overall effect: Z =	9; Chi² = 0.81 (P ∺ DI Nev Even 18	rer-B ts 1 2 38	2) F <u>Fotal</u> 29 260	Any Event	7 -BF 5 Tot 5 6 7 77	<mark>al W</mark> 9 5 9	<mark>/eight</mark> 0.3% 99.7%	Risk Ratio IV, Fixed, 95% Cl 0.95 [0.20, 4.63] 1.17 [1.07, 1.29]	-1 -0.3 0 0.5 1 Never-BF Any-BF Risk Ratio IV, Fixed, 95% Cl
Heterogeneity: Tau ² = 0.05 Test for overall effect: Z = - 2.3. Incidence of NI Study or Subgroup Furman 2004 Vohr 2006 Total (95% CI)	9; Chi² = 0.81 (P ∺ DI Nev Even	rer-B ts 1 2 38	2) F F Cotal 29 260 289	Any <u>Event</u> 47	7 -BF <u>s Tot</u> 5 6 7 77 84	al W 19 15 9 4 1(<u>/eight</u> 0.3% 99.7% 00.0%	Risk Ratio IV. Fixed, 95% CI 0.95 [0.20, 4.63] 1.17 [1.07, 1.29] 1.17 [1.07, 1.29]	-1 -0.5 0 0.5 1 Never-BF Any-BF Risk Ratio
Heterogeneity: Tau ² = 0.05 Test for overall effect: Z = - 2.3. Incidence of NI Study or Subgroup Furman 2004 Vohr 2006 Total (95% CI) Total events	9; Chi ² = 0.81 (P DI Nev Even 18	er-B ts 7 2 38	2) F F 29 260 289	Any <u>Event</u> 47 ⁻ 48	7-BF <u>s Tot</u> 5 6 7 77 84 2	al W 39 75 9 4 10	/eight 0.3% 99.7% 00.0%	Risk Ratio IV, Fixed, 95% Cl 0.95 [0.20, 4.63] 1.17 [1.07, 1.29] 1.17 [1.07, 1.29]	-1 -0.5 0 0.5 1 Never-BF Any-BF Risk Ratio <u>IV, Fixed, 95% CI</u>
Heterogeneity: Tau ² = 0.05 Test for overall effect: Z = - 3.3. Incidence of NI Study or Subgroup Furman 2004 Vohr 2006 Total (95% CI) Total events Heterogeneity: Chi ² = 0	9; Chi² = 0.81 (P ⁻ DI <u>Nev</u> <u>Even</u> 18 0.07, df	er-B ts] 2 38	2) F <u>F</u> 29 260 289 (P = 0	Any <u>Event</u> 47 48	7 -BF <u>s Tot</u> 5 6 7 77 84 2 = 0%	al W 19 15 9 4 10	/eight 0.3% 99.7% 00.0%	Risk Ratio IV, Fixed, 95% Cl 0.95 [0.20, 4.63] 1.17 [1.07, 1.29] 1.17 [1.07, 1.29]	-1 -0.3 0 0.5 1 Never-BF Any-BF
Heterogeneity: Tau ² = 0.05 Test for overall effect: Z = 1 2.3. Incidence of NI Study or Subgroup Furman 2004 Vohr 2006 Total (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2	9; Chi ² = 0.81 (P ⁻ DI <u>Nev</u> 18 18 0.07, df Z = 3.3	er-B er-B 1 <u>ts</u> 2 38 90 = 1 7 (P	2) F Total 29 260 289 (P = 0 = 0.00	Any <u>Event</u> 47 ⁻ 48: (.79); I ² (.79); I ²	7- BF 5 6 7 77 84 2 = 0%	<u>al W</u> 9 5 9 4 10	/eight 0.3% 99.7% 00.0%	Risk Ratio IV. Fixed. 95% CI 0.95 [0.20, 4.63] 1.17 [1.07, 1.29] 1.17 [1.07, 1.29] 0.1	-1 -0.3 0 0.5 1 Never-BF Any-BF Risk Ratio IV, Fixed, 95% CI ↓ ↓ ↓ ↓ ↓ ↓ 0.2 0.5 1 2 5 10
Heterogeneity: Tau ² = 0.05 Test for overall effect: Z = 1 2.3. Incidence of NI Study or Subgroup Furman 2004 Vohr 2006 Total (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2	9; Chi ² = 0.81 (P DI <u>Nev</u> 18 18 0.07, df Z = 3.3	er-B er-B 2 38 90 f = 1 7 (P	2) F Total 29 260 289 (P = 0 = 0.00	Any <u>Event</u> 47 ⁻ 48; 9.79); I ² 008)	5 F 5 6 7 77 84 2 = 0%	<u>al W</u> 9 5 9 4 10	/eight 0.3% 99.7% 00.0%	Risk Ratio IV. Fixed. 95% CI 0.95 [0.20, 4.63] 1.17 [1.07, 1.29] 1.17 [1.07, 1.29] 	-1 -0.5 0 0.5 1 Never-BF Any-BF Risk Ratio IV. Fixed, 95% CI ↓ ↓ ↓ ↓ ↓ 0.2 0.5 1 2 5 10 Never-BF Any-BF
Heterogeneity: Tau ² = 0.05 Test for overall effect: Z = - .3. Incidence of NI <u>Study or Subgroup</u> Furman 2004 Vohr 2006 Total (95% CI) Total events Heterogeneity: Chi ² = 0 Test for overall effect: 2	9; Chi ² = 0.81 (P ⁻ DI Nev 218 18 0.07, df Z = 3.3	er-B t <u>ts</u> 2 38 90 7 (P	2) F <u>F</u> 29 260 289 (P = 0 = 0.00	Any Event 47 48: 1.79); l ² 008)	7-BF <u>s Tot</u> 5 6 7 77 84 2 = 0%	al W 9 5 9 4 10	/eight 0.3% 99.7% 00.0%	Risk Ratio IV, Fixed, 95% CI 0.95 [0.20, 4.63] 1.17 [1.07, 1.29] 1.17 [1.07, 1.29] 0.1	-1 -0.3 0 0.5 1 Never-BF Any-BF Risk Ratio IV, Fixed, 95% CI 0.2 0.5 1 2 5 10 Never-BF Any-BF

1.07, 1.29, p=0.0008, Figure 2; very low certainty evidence; 2 observation studies, 1,133 participants, Supplementary Table S7), with no significant heterogeneity ($I^2=0\%$, p=0.79, Figure 2).

Overall, Any-BF is associated with enhanced cognitive outcomes and a possible reduction in NDI incidence in preterm infants, although evidence on motor development remains inconclusive.

3.6 Predominate preterm formula versus predominate breastfeeding (n = 11)

Eleven studies (31, 36, 47–50, 52–56) investigated the dose effect of breastfeeding on neurodevelopment, with 10 employing the BSID -II/III for cognitive, language, or motor assessment at various ages (6, 12, 18, 20, or 24 months), and 1 (47) using the KABC at 5 years of age. Ten cohort studies (36, 47–50, 52–56) were included in the metaanalysis. The study by Belfort et al. (31) was excluded from the metaanalysis because it primarily focused on the effect of breastfeeding on brain volume in very preterm infants at 7 years old and did not provide neurodevelopmental scores with means and standard deviations. However, the study reported a positive association between IQ and the number of days receiving >50% BF (0.5 points/day, 95% CI 0.2, 0.8).

3.6.1 Cognitive scores

The meta-analysis, comprising 10 studies, found no statistically significant difference in cognitive outcomes between the Pre-PTF groups and the Pre-BF groups (SMD 0.17, 95% CI -0.02, 0.36, p=0.08, Figure 3; low certainty evidence; 10 observation studies, 1,903 participants, Supplementary Table S7). However, substantial heterogeneity was present (I^2 =68%, p=0.0009, Figure 3), necessitating the use of a random effects model for evaluation and subsequent subgroup analysis.

Additionally, the subgroup analysis revealed a higher pooled SMD in cognitive scores for infants with less than 18 months of follow-up (SMD 0.19, 95% CI 0.03, 0.35, p=0.02, Supplementary Table S6). The heterogeneity observed may be attributed to the disparate assessment points and the varying doses of breast milk consumed.

3.6.2 Language scores

Four trials contributed data to the meta-analysis on language scores, showing no significant difference within a random effects model despite substantial heterogeneity (SMD 0.27, 95% CI -0.01, 0.55, p=0.06, $I^2=57\%$, Figure 3; very low certainty evidence; 4 observation studies, 605 participants, Supplementary Table S7).

Subgroup analysis revealed no meaningful differences based on GA, BW, or maternal education/IQ (see Supplementary Table S6). Heterogeneity may be due to the varying doses of breast milk.

3.6.3 Motor scores

Ten studies contributed to motor score analysis and found no differences in motor development outcomes with a substantial heterogeneity (SMD 0.11, 95% CI -0.05, 0.28, I^2 =56%, p=0.17, Figure 3; very low certainty evidence; 10 observation studies, 1,900



participants, Supplementary Table S7), between the Pre-PTF groups and the Pre-BF groups. The same heterogeneity applies.

Subgroup analysis was conducted concerning different assessment points and infant characteristics due to potential biases. No significant differences were observed in the subgroups, except in the study by Tanaka et al. (47), which suggested that heightened breastfeeding levels in preterm infants during the neonatal period may notably influence brain development, especially in motor function at 5 years (SMD -1.37, 95% CI -2.42,-0.31, p = 0.01, Supplementary Table S6).

3.6.4 Incidence of neurodevelopmental impairment

In the present meta-analysis, we included only 1 studies, which were conducted by Furman et al. (36) try to explore the correlation between the incidence of NDI and breastfeeding, to focusing on the impact of various breastfeeding dosages, and found no significant difference (RR 1.02, 95% CI 0.18, 5.74, p = 0.98, Figure 3; very low certainty evidence; 1 observation studies, 69 participants, Supplementary Table S7).

Overall, the evidence comparing Pre-PTF and Pre-BF on neurodevelopment is inconclusive, with no significant differences in cognitive, language, motor outcomes, or NDI.

3.7 Predominate preterm formula vs. predominate donor breast milk

Three studies (51, 52, 54) compared the NDOs of Pre-PTF versus Pre-DBM in preterm infants, including 1 RCT and 2 cohort studies. The BSID-III was utilized for evaluation of NDOs between 18 and 24 months of age in all studies. Given the potential for heterogeneity resulting from the use of disparate research designs, we conducted separate meta-analyses of RCT studies and observational studies.

3.7.1 Cognitive scores

In the two cohort studies, the Pre-PTF group showed superior cognitive outcomes to the Pre-DBM groups (SMD 0.51, 95% CI 0.26, 0.75, $I^2 = 0\%$, p < 0.0001, Figure 4; low certainty evidence; 2 observation studies, 281 participants, Supplementary Table S7), while the RCT did not find any significant differences (SMD 0.08, 95% CI -0.14, 0.31, p = 0.47, Figure 4; Moderate certainty evidence; 1 RCT, 299 participants, Supplementary Table S7). No heterogeneity was observed (Cohort studies: $I^2 = 0\%$, p = 0.46; RCTs: Heterogeneity Not applicable; Figure 4).

3.7.2 Language scores

In both cohort studies and RCT, the language outcomes for the Pre-DBM groups and Pre-PTF groups did not differ significantly (Cohort studies: SMD 0.17, 95% CI -0.06, 0.41, p=0.15, Figure 4, low certainty evidence; 2 observation studies, 299 participants, Supplementary Table S7; RCTs: SMD 0.14, 95% CI -0.09, 0.36, p=0.24, Figure 4, Moderate certainty evidence; 1 RCT, 299 participants, Supplementary Table S7), and there was no significant heterogeneity (Cohort studies: I^2 =20%, p=0.26; RCTs: Heterogeneity Not applicable; Figure 4).

3.7.3 Motor scores

Similarly, in both cohort studies and RCT, motor scores did not exhibit any significant differences (Cohort studies: SMD 0.10, 95% CI -0.14, 0.33, p = 0.42, low certainty evidence; 2 observation studies, 299 participants, Supplementary Table S7; RCTs: SMD 0.12, 95% CI -0.11, 0.34, p = 0.31, Figure 4, Moderate certainty evidence; 1 RCT, 299 participants, Supplementary Table S7). The heterogeneity was not significant (Cohort studies: P = 0%, p = 0.77; RCTs: Heterogeneity Not applicable; Figure 4).

3.7.4 Incidence of neurodevelopmental impairment

Only the RCT (51) study provided data on the incidence of NDI, but no statistically significant differences were observed (RR 0.87, 95% CI 0.42, 1.83, p=0.72, Heterogeneity Not applicable; Figure 4, Moderate certainty evidence; 1 RCT, 299 participants, Supplementary Table S7).

Overall, the evidence comparing Pre-PTF and Pre-DBM on cognitive function is inconclusive. No significant differences were observed in language, motor skills, or the incidence of NDI between the two feeding groups.

3.8 Publication bias and sensitivity analysis of the meta-analysis in observation studies

Supplementary Figures S1–S5 display funnel plots representing NDOs based on different feeding strategies. Publication bias was identified for the pooled effect sizes of motor development outcomes in preterm infants when comparing those fed Pre-PTF with those who received Pre-BF (Egger's test: p = 0.048). This bias suggests a shortage of studies with larger sample sizes and effect sizes. Sensitivity analysis revealed that the pooled effect sizes shifted when individual studies were excluded. Specifically, the exclusion of Vohr et al. (46) altered the cognitive outcomes comparison between the Never-BF and Any-BF groups (effect size: -0.065, 95% CI: -0.299 to 0.169; Supplementary Table S5), indicating that this study significantly influenced the overall results. It is imperative to exercise caution when interpreting this finding, as heterogeneity and publication bias have the potential to impact its validity and generalizability.

4 Discussion

4.1 Summary of main findings

This systematic review and meta-analysis examined the association between breastfeeding and NDOs in preterm infants. The review encompassed studies from the past two decades, including 15 observational studies involving 3,619 preterm infants and one RCT with 363 preterm infants. Of these, 14 studies were included in the meta-analyses, while 2 studies involving 300 infants were synthesized narratively. We observed consistent evidence suggesting enhanced cognitive development in preterm infants who received any breastfeeding compared to those who were never breastfed, as well as a reduced risk of neurodevelopmental impairment. These findings reinforce existing recommendations for breastfeeding in preterm infants, highlighting its beneficial impact on cognitive abilities and the decreased likelihood of neurodevelopmental disorders. However, the effect of breastfeeding on motor development remains inconclusive. There is a slight positive effect of breastfeeding observed in infants born before 28 weeks of gestation or weighing less than 1,000 grams, indicating a need for further investigation. Additionally, the comparative superiority of exclusive breastfeeding, DBM, and various doses of breastfeeding versus PTF concerning long-term NDOs in preterm infants remains inconclusive. The variability in demographic characteristics, testing times, and the diversity of assessments employed further complicated the analysis of this outcome. Furthermore, the overall quality of the evidence for most results was assessed as low to very low, which significantly limits the credibility of the findings.

4.2 Strengths and weaknesses

A robust search strategy across eight electronic databases, adhering to Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines, provided a comprehensive review of both RCTs and cohort studies, relevant to neonatal clinicians and parental decision-making, particularly concerning DBM. The high rate of premature births in China raises significant public health concerns, as

		0-1 11		Pro	e-DRIV	1		Std. Mean Difference	e		Stu. mea	an Difference		
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Fixed, 95%			IV, Fix	<u>ced, 95% Cl</u>		
I.1.1 Cohort Studies														
lair 2022	96.5	15.1	101	89.6	14.1	151	42.0%	0.47 [0.22, 0.7	'3]				_	
Madore 2017	94.7	15.1	13	83.1	13.9	16	4.7%	0.78 [0.02, 1.5	54]					
Subtotal (95% CI)			114			167	46.7%	0.51 [0.26, 0.7	5]					
leterogeneity: Chi ² = 0).56, df =	= 1 (P	= 0.46)	; I ² = 0%	6									
est for overall effect: 2	Z = 4.09	(P < 0).0001)											
142 0010														
N. 1.2 KG15	04 5	10.0	110	02.0	10.1	151	E2 20/	0.0910.14.0.2	41			_ 		
Subtotal (95% CI)	94.5	10.9	140	92.9	19.1	151	53.3%	0.08 [-0.14, 0.3	11					
leterogeneity: Not ann	licable		140			101	00.070	0.00 [-0.14, 0.0	.1					
lest for overall effect: 2	7 = 0.73	(P = 0)) 47)											
	_ 0.70	(. c	,											
fotal (95% CI)			262			318	100.0%	0.28 [0.12, 0.4	5]			-		
leterogeneity: Chi ² = 6	6.74, df =	= 2 (P	= 0.03)	; I ² = 70)%									
est for overall effect: 2	Z = 3.32	(P = 0	0.0009)							-1	-0.5 Dro_DT	U U.5	1	
est for subaroup diffe	rences:	Chi² =	6.19. d	lf = 1 (P	= 0.0	1). I² =	83.8%				FIG-FI			
2. Language Sco	ores	DTE			NBM			Std. Maan Difforance	~		Std Mon	n Difforonco		
Study or Subgroup	Moan		Total	Moan		Total	Weight	IV Fixed 95%			IV Fiv	an Difference		
2.1 Cohort Studies	mean	50	iotal	mean	50	Total	weight	19, 1 IACU, 3370	, 01					
lair 2022	85 5	15	101	82.2	14 1	151	41 7%	0.23 [-0.03 .0.4	181			⊢ ∎−−		
Andore 2017	88	15.5	34	88.7	17.3	13	6.5%	-0 17 [-0.81 04	.7]	-				
Subtotal (95% CI)	50	.0.0	135	50.1		164	48.2%	0.17 [-0.06. 0.4	1]					
leterogeneity: Chi ² = 1	.26. df =	= 1 (P	= 0.26)	: l ² = 20)%									
est for overall effect: 2	Z = 1.45	(P = 0).15)											
.2.2 RCTs														
D'Connor 2016	90.3	22.3	148	87.3	21.9	151	51.8%	0.14 [-0.09, 0.3	6]					
Subtotal (95% CI)			148			151	51.8%	0.14 [-0.09, 0.3	6]					
leterogeneity: Not app	olicable													
Test for overall effect: 2	Z = 1.17	(P = 0).24)											
							100.00/							
otal (95% CI)			283			315	100.0%	0.15 [-0.01, 0.32	2]					
leterogeneity: Chi ² = 1	31 df:	– 0 (D	-0 E0	12 00								1 1		
		= 2 (P	= 0.52)	; I ² = 0%	6					-1	-0.5	0 0.5	1	
est for overall effect: 2	Z = 1.85	= 2 (P (P = 0	= 0.52)).06)	; I ² = 09	% 0	<u>-</u>	00/			-1	-0.5 PT	0 0.5 F DBM	1	
est for overall effect: 2 est for subaroup differ	Z = 1.85 rences:	= 2 (P (P = 0 Chi ² =	= 0.52)).06) 0.05. d	i; I² = 0% If = 1 (P	% 9 = 0.8	2). ² =	0%			-1	-0.5 PT	0 0.5 F DBM	1	
Test for overall effect: 2 Test for subaroup differ 3. Motor Scores	Z = 1.85 rences:	= 2 (P (P = 0 Chi ² = PTF	= 0.52)).06) 0.05. d	i; i² = 0%	% ? = 0.8 DBM	2). ² =	0%	Std. Mean Differenc		-1	-0.5 PT Std. Mea	0 0.5 F DBM an Difference	1 e	
Test for overall effect: 2 Test for subaroup differ 3. Motor Scores <u>Study or Subgroup</u>	Z = 1.85 rences: Mean	= 2 (P (P = 0 Chi ² = PTF SD	= 0.52)).06) 0.05. d	; I² = 09 If = 1 (P <u>Mean</u>	% ? = 0.8 DBM SD	2). ² = Tota l	0% Weight	Std. Mean Differenc IV, Fixed, 95%	ce 6 Cl	-1	-0.5 PT Std. Mea IV, Fiz	0 0.5 F DBM an Difference xed, 95% Cl	1 e	
Test for overall effect: 2 Test for subaroup differ 3. Motor Scores <u>Study or Subgroup</u> 4.3.1 Cohort Studies	Z = 1.85 rences: Mean	= 2 (P (P = 0 Chi ² = PTF SD	= 0.52)).06) 0.05. d <u>Total</u>	;	% 9 = 0.8; DBM SD	2). ² = Tota	0% Weight	Std. Mean Differenc IV, Fixed, 95%	ce 6 Cl	-1	-0.5 PT Std. Mea IV, Fiz	0 0.5 F DBM an Difference xed, 95% Cl	1 9	
est for overall effect: 2 Test for subgroup differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022	Z = 1.85 rences: Mean 92.9	$= 2 (P)^{2}$ (P = 0) Chi ² = PTF <u>SD</u> 11.7	= 0.52) 0.06) 0.05. d <u>Total</u> 101	if = 1 (P <u>Mean</u> 91.4	% P = 0.8 DBM <u>SD</u> 14.6	2). ² = <u>Tota</u> 151	0% <u>Weight</u> 41.8%	Std. Mean Differenc IV. Fixed, 95% 0.11 [-0.14, 0.3	ce <u>6 CI</u> 36]	-1	-0.5 PT Std. Mea <u>IV, Fi</u> 2	0 0.5 F DBM an Difference xed. 95% Cl	1	
Test for overall effect: 2 Test for subgroup differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022 Madore 2017	Z = 1.85 rences: Mean 92.9 88.8	= 2 (P (P = 0 Chi ² = PTF SD 11.7 13.9	= 0.52) 0.06) 0.05. d <u>Total</u> 101 34	; ² = 09 If = 1 (P <u>Mean</u> 91.4 88.7	[%] = 0.8 DBM SD 14.6 17.3	2). ² = <u>Tota</u> 151 13	0% Weight 41.8% 6.5%	Std. Mean Difference IV. Fixed, 95% 0.11 [-0.14, 0.3 0.01 [-0.63, 0.6	ce <u>6 Cl</u> 36] 65]	-1	-0.5 PT Std. Mea IV, Fiz	0 0.5 F DBM an Difference <u>xed, 95% Cl</u>	1	
est for overall effect: 2 rest for subgroup differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022 Vadore 2017 Subtotal (95% CI)	Z = 1.85 rences: <u>Mean</u> 92.9 88.8	= 2 (P = C (P = C Chi ² = PTF SD 11.7 13.9	= 0.52) 0.06) 0.05. d <u>Total</u> 101 34 135	; ² = 09 If = 1 (P <u>Mean</u> 91.4 88.7	% DBM SD 14.6 17.3	2). ² = Tota 151 13 164	0% Weight 41.8% 6.5% 48.3%	Std. Mean Difference IV. Fixed. 95% 0.11 [-0.14, 0.3 0.01 [-0.63, 0.6 0.10 [-0.14, 0.3	ce <u>6 CI</u> 36] 65] 33]	-1	-0.5 PT Std. Mea IV, Fi;	0 0.5 F DBM an Difference <u>xed, 95% Cl</u>	1	
Test for overall effect: 2 Test for subgroup differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022 Madore 2017 Subtotal (95% Cl) Heterogeneity: Chi ² = 1	Z = 1.85 rences: <u>Mean</u> 92.9 88.8 0.09, df	= 2 (P = 0 (P = 0 Chi ² = PTF <u>SD</u> 11.7 13.9 = 1 (P	= 0.52) 0.06) 0.05. d 101 34 135 = 0.77	; i ² = 09 If = 1 (P <u>Mean</u> 91.4 88.7); i ² = 0 ⁰	% DBM 14.6 17.3 %	2). I ² = <u>Total</u> 151 13 164	0% Weight 41.8% 6.5% 48.3%	Std. Mean Difference IV. Fixed. 95% 0.11 [-0.14, 0.3 0.01 [-0.63, 0.6 0.10 [-0.14, 0.3	ce 6 CI 36] 35] 33]	-1	-0.5 PT Std. Mea IV, Fiz	0 0.5 F DBM an Differenc: <u>xed, 95% Cl</u>	1	
est for overall effect: 2 Test for subgroup differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022 Madore 2017 Subtotal (95% Cl) Heterogeneity: Chi ² = 1 Test for overall effect:	Z = 1.85 rences: <u>Mean</u> 92.9 88.8 0.09, df Z = 0.81	= 2 (P ⁻¹ (P = C Chi ² = PTF 3D 11.7 13.9 = 1 (P 1 (P = 0	= 0.52) 0.06) 0.05. d Total 101 34 135 = 0.77 0.42)	i; i ² = 09 if = 1 (P <u>Mean</u> 91.4 88.7); i ² = 0 ⁶	% P = 0.8 DBM SD 14.6 17.3	2). ² = Tota 151 13 164	0% Weight 41.8% 6.5% 48.3%	Std. Mean Difference IV. Fixed. 95% 0.11 [-0.14, 0.3 0.01 [-0.63, 0.6 0.10 [-0.14, 0.3	ce 6 CI 36] 35] 33]	-1	-0.5 PT Std. Mea IV, Fiz	0 0.5 F DBM an Difference xed, 95% CI	1	
est for overall effect: 2 est for subgroup differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022 Wadore 2017 Subtotal (95% CI) Heterogeneity: Chi ² = 1 Test for overall effect: 4.3.2 RCTs	Z = 1.85 rences: <u>Mean</u> 92.9 88.8 0.09, df Z = 0.81	= 2 (P ⁻¹ 6 (P = C Chi ² = PTF 5D 11.7 13.9 = 1 (P 1 (P = 0	= 0.52) 0.06) 0.05. d 101 34 135 = 0.77 0.42)	if = 1 (P <u>Mean</u> 91.4 88.7); I ² = 0 ^c	% DBM <u>SD</u> 14.6 17.3	2). ² = <u>Tota</u> 151 13 164	0% <u>Weight</u> 41.8% 6.5% 48.3%	Std. Mean Differenc IV. Fixed, 95% 0.11 [-0.14, 0.3 0.01 [-0.63, 0.6 0.10 [-0.14, 0.3	 6 CI 36] 65] 33]	-1	-0.5 PT Std. Mea IV, Fiz	0 0.5 F DBM an Difference xed, 95% CI	1	
est for overall effect: 2 est for subgroup differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022 Wadore 2017 Subtotal (95% Cl) Heterogeneity: Chi ² = 1 Test for overall effect: 4.3.2 RCTs D'Connor 2016	Z = 1.85 rences: <u>Mean</u> 92.9 88.8 0.09, df Z = 0.81	= 2 (P ⁻¹ (P = C) Chi ² = PTF SD 11.7 13.9 = 1 (P 1 (P = 0)	= 0.52) 0.06) 0.05. d 101 34 135 = 0.77 0.42)	(; I ² = 09 if = 1 (P <u>Mean</u> 91.4 88.7); I ² = 0 ⁰ 01 P	6 DBM SD 14.6 17.3 %	2). ² = <u>Total</u> 151 13 164 151	0% Weight 41.8% 6.5% 48.3% 51.7%	Std. Mean Difference IV. Fixed, 95% 0.11 [-0.14, 0.3 0.01 [-0.63, 0.6 0.10 [-0.14, 0.3	ce 6 Cl 36] 55] 33]	-1	-0.5 PT Std. Mea IV. Fiz	0 0.5 F DBM an Difference xed, 95% CI	1 •	
est for overall effect: 2 est for subgroup differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022 Wadore 2017 Subtotal (95% Cl) Heterogeneity: Chi ² = 1 Test for overall effect: 4.3.2 RCTs D'Connor 2016 Subtotal (95% Cl)	Z = 1.85 rences: 92.9 88.8 0.09, df Z = 0.81	= 2 (P ⁻¹ (P = C Chi ² = PTF 11.7 13.9 = 1 (P 1 (P = 0 18.6	= 0.52) 0.06) 0.05. d 101 34 135 = 0.77 0.42) 148 148	; I ² = 09 If = 1 (P <u>Mean</u> 91.4 88.7); I ² = 0 ⁶ 91.8	% DBM 14.6 17.3 % 19.1	2). ² = <u>Total</u> 151 13 164 151 151	0% Weight 41.8% 6.5% 48.3% 51.7% 51.7%	Std. Mean Difference IV, Fixed, 95% 0.11 [-0.14, 0.3 0.01 [-0.63, 0.6 0.10 [-0.14, 0.3 0.12 [-0.11, 0.3 0.12 [-0.11, 0.3	ce 6 Cl 36] 55] 33] 34]	-1	-0.5 PT Std. Mea IV. Fiz	0 0.5 F DBM an Difference xed, 95% CI	1	
est for overall effect: 2 Test for subgroup differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022 Wadore 2017 Subtotal (95% CI) Heterogeneity: Chi ² = 1 Test for overall effect: 4.3.2 RCTs D'Connor 2016 Subtotal (95% CI) Heterogeneity: Not app	2 = 1.85 rences: <u>Mean</u> 92.9 88.8 0.09, df Z = 0.81 94	= 2 (P 6 (P = 0 Chi ² = PTF 11.7 13.9 = 1 (P 1 (P = 0 18.6	= 0.52) 0.06) 0.05. d 101 34 135 = 0.77 0.42) 148 148	; I ² = 09 If = 1 (P <u>Mean</u> 91.4 88.7); I ² = 0 ⁴ 91.8	* = 0.8: DBM 14.6 17.3 % 19.1	2). ² = <u>Tota</u> 151 13 164 151 151	0% Weight 41.8% 6.5% 48.3% 51.7% 51.7%	Std. Mean Differenc IV, Fixed, 95% 0.11 [-0.14, 0.3 0.01 [-0.14, 0.3 0.10 [-0.14, 0.3 0.12 [-0.11, 0.3 0.12 [-0.11, 0.3	5e 6 Cl 36] 35] 33] 34]	-1	-0.5 PT Std. Mea IV. Fiz	0 0.5 F DBM an Differenco xed. 95% CI	1	
est for overall effect: 2 Test for subgroup differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022 Subtotal (95% CI) Heterogeneity: Chi ² = 1 Test for overall effect: 4.3.2 RCTs D'Connor 2016 Subtotal (95% CI) Heterogeneity: Not app Test for overall effect:	Z = 1.85 rences: <u>Mean</u> 92.9 88.8 0.09, df Z = 0.81 94 plicable Z = 1.01	$= 2 (P)^{2}$ $(P = 0)^{2}$ $Chi^{2} = 0$ PTF $5D$ 11.7 13.9 $= 1 (P)$ $1 (P = 0)$ 18.6 $1 (P = 0)$	= 0.52) 0.06) 0.05. d 101 34 135 = 0.77 0.42) 148 148 148 0.31)	; I ² = 09 If = 1 (P <u>Mean</u> 91.4 88.7); I ² = 0 ⁴ 91.8	% DBM 14.6 17.3 % 19.1	2). ² = Total 151 13 164 151 151	0% 41.8% 6.5% 48.3% 51.7% 51.7%	Std. Mean Difference IV, Fixed, 95% 0.11 [-0.14, 0.3 0.01 [-0.63, 0.6 0.10 [-0.14, 0.3 0.12 [-0.11, 0.3 0.12 [-0.11, 0.3	ce 6 <u>6 Cl</u> 36] 36] 33] 34] 34]	-1	-0.5 PT Std. Mea IV. Fiz	0 0.5 F DBM	-	
Test for overall effect: 2 Test for subgroup differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022 Madore 2017 Subtotal (95% CI) Heterogeneity: Chi ² = 1 Test for overall effect: 4.3.2 RCTs O'Connor 2016 Subtotal (95% CI) Heterogeneity: Not app Test for overall effect:	Z = 1.85 rences: 92.9 88.8 0.09, df Z = 0.81 94 plicable Z = 1.01	$= 2 (P)^{2}$ $(P = 0)^{2}$ $Chi^{2} = 0^{2}$ PTF $3D$ $= 1 (P)^{2}$ $1 (P = 0)^{2}$ $1 (P = 0)^{2}$ $1 (P = 0)^{2}$	$\begin{array}{c} = 0.52)\\ 0.06)\\ 0.05. d\\ \hline \\ 101\\ 34\\ 135\\ = 0.77\\ 0.42)\\ 148\\ 148\\ 148\\ 0.31)\end{array}$; I ² = 0% If = 1 (P <u>Mean</u> 91.4 88.7); I ² = 0° 91.8	% P = 0.8: DBM 14.6 17.3 %	2). ² = <u>Total</u> 151 13 164 151 151	0% 41.8% 6.5% 48.3% 51.7% 51.7%	Std. Mean Difference IV, Fixed, 95% 0.11 [-0.14, 0.3 0.01 [-0.63, 0.6 0.10 [-0.14, 0.3 0.12 [-0.11, 0.3 0.12 [-0.11, 0.3	5e 6 CI 36] 36] 33] 33] 34]	-1	-0.5 PT Std. Mea IV. Fiz	0 0.5 F DBM	-	
Test for overall effect: 2 Test for subgroup differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022 Madore 2017 Subtotal (95% CI) Heterogeneity: Chi ² = 1 Test for overall effect: 4.3.2 RCTs O'Connor 2016 Subtotal (95% CI) Heterogeneity: Not app Test for overall effect: Total (95% CI)	Z = 1.85 rences: 92.9 88.8 0.09, df Z = 0.81 94 plicable Z = 1.01	$= 2 (P^{-1})^{-1} (P = 0)^{-1} (P = 0)^{-1$	= 0.52) 0.06) 0.05. d 101 34 135 = 0.77 0.42) 148 148 0.31) 283	; I ² = 0% If = 1 (P <u>Mean</u> 91.4 88.7); I ² = 0° 91.8	% DBM 14.6 17.3 %	2). ² = <u>Total</u> 151 13 164 151 151 315	0% 41.8% 6.5% 48.3% 51.7% 51.7% 51.7% 100.0%	Std. Mean Difference IV, Fixed, 95% 0.11 [-0.14, 0.3 0.01 [-0.63, 0.6 0.10 [-0.14, 0.3 0.12 [-0.11, 0.3 0.12 [-0.11, 0.3 0.11 [-0.06, 0.2	26 <u>6</u> CI 36] 35] 33] 34] 34] 27]	-1	-0.5 PT Std. Mea IV. Fi;	0 0.5 F DBM	1	
est for overall effect: 2 Test for subcroup differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022 Madore 2017 Subtotal (95% CI) Heterogeneity: Chi ² = 1 A.3.2 RCTs D'Connor 2016 Subtotal (95% CI) Heterogeneity: Not app Test for overall effect: Total (95% CI) Heterogeneity: Chi ² = 1	2 = 1.85 rences: 92.9 88.8 0.09, df Z = 0.81 94 plicable Z = 1.01 0.10, df	<pre>2 (P = 2 (P = 0 Chi² = 0 Chi² = 0 TF SD 11.7 13.9 = 1 (P = 1)))))))))))))))))))))))))))))))))))</pre>	$\begin{array}{r} = 0.52)\\ 0.06)\\ 0.05. d\\ \hline \\ 101\\ 34\\ 135\\ = 0.77\\ 0.42)\\ 148\\ 148\\ 0.31)\\ 283\\ = 0.95\end{array}$	$(1^{2} + 1^{2} + 1^{2})$ $(1^{2} + 1^{2})$ $(1^$	% P = 0.8; DBM <u>SD</u> 14.6 17.3 % 19.1	2). ² = <u>Total</u> 151 13 164 151 151 315	0% Weight 41.8% 6.5% 48.3% 51.7% 51.7% 100.0%	Std. Mean Difference IV, Fixed, 95% 0.11 [-0.14, 0.3 0.01 [-0.63, 0.6 0.10 [-0.14, 0.3 0.12 [-0.11, 0.3 0.12 [-0.11, 0.3 0.11 [-0.06, 0.2	26 <u>6</u> Cl 36] 36] 33] 34] 34] 34] 27]	-1	-0.5 PT Std. Mea IV. Fi;	0 0.5 F DBM	1	
Test for overall effect: 2 Test for subaroup differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022 Madore 2017 Subtotal (95% CI) Heterogeneity: Chi ² = (4.3.2 RCTs O'Connor 2016 Subtotal (95% CI) Heterogeneity: Not app Test for overall effect: Total (95% CI) Heterogeneity: Chi ² = (Total (95% CI) Heterogeneity: Chi ² = (Total (95% CI)	Z = 1.85 rences: 92.9 88.8 0.09, df Z = 0.81 94 plicable Z = 1.01 0.10, df Z = 1.28	PTF = 2 (P = 0) $PTF = SD$ $11.7 + 13.9$ $1 (P = 0)$ $1 (P = 0)$ $1 (P = 0)$ $1 (P = 0)$ $2 (P = 0)$ $2 (P = 0)$	0.06) 0.06) 0.05. c 101 34 135 = 0.77 0.42) 148 148 0.31) 283 = 0.95 0.20)	$(; l^{2} = 0^{\circ})$ lf = 1 (P) <u>Mean</u> 91.4 88.7); l^{2} = 0^{\circ} 91.8); l^{2} = 0^{\circ}	% P = 0.8; DBM <u>SD</u> 14.6 17.3 % 19.1	2). ² = <u>Total</u> 151 13 164 151 151 315	0% Weight 41.8% 6.5% 48.3% 51.7% 51.7% 100.0%	Std. Mean Differenc IV. Fixed, 95% 0.11 [-0.14, 0.3 0.01 [-0.63, 0.6 0.10 [-0.14, 0.3 0.12 [-0.11, 0.3 0.12 [-0.11, 0.3 0.11 [-0.06, 0.2	26 6 Cl 36] 35] 33] 34] 34]	-1 -1 -1	-0.5 PT Std. Mea IV. Fi; -0.5	0 0.5 F DBM	1	
Test for overall effect: 2 Test for subaroub differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022 Madore 2017 Subtotal (95% CI) Heterogeneity: Chi ² = (A.3.2 RCTs O'Connor 2016 Subtotal (95% CI) Heterogeneity: Not app Test for overall effect: Total (95% CI) Heterogeneity: Chi ² = (Test for overall effect: Total (95% CI) Heterogeneity: Chi ² = (Test for overall effect: Total (95% CI)	Z = 1.85 rences: Mean 92.9 88.8 0.09, df Z = 0.81 94 plicable Z = 1.01 0.10, df Z = 1.28 rences:	$PTF = 2 (P = 0)$ $PTF = SD$ $11.7 + 13.9$ $11.7 + 10.9$ $1 (P = 0)$ $1 (P = 0)$ $1 (P = 0)$ $1 (P = 0)$ $2 (P = 0)$ $2 (P = 0)$ $Chi^{2} = 0$	0.06) 0.06) 0.05. c 101 34 135 = 0.77 0.42) 148 148 0.31) 283 = 0.95 0.20) 0.01. c	$(; I^{2} = 0^{\circ})$ If = 1 (P) 91.4 88.7 $(; I^{2} = 0^{\circ})$ 91.8 $(; I^{2} = 0^{\circ})$ 91.8 $(; I^{2} = 0^{\circ})$ $(; I^{2} = 0^{\circ})$	% P = 0.8: DBM 14.6 17.3 % 19.1 % % P = 0.9	2). ² = <u>Total</u> 151 13 164 151 151 315 1). ² =	0% Weight 41.8% 6.5% 48.3% 51.7% 51.7% 100.0% 0%	Std. Mean Differenc IV. Fixed, 95% 0.11 [-0.14, 0.3 0.01 [-0.63, 0.6 0.10 [-0.14, 0.3 0.12 [-0.11, 0.3 0.12 [-0.11, 0.3 0.11 [-0.06, 0.2	26 6 Cl 36] 35] 33] 34] 34]	-1 -1 -1	-0.5 PT Std. Mea IV, Fi; -0.5 P1	0 0.5 F DBM	1 - - 1	
Test for overall effect: 7 Test for subaroub differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022 Madore 2017 Subtotal (95% CI) Heterogeneity: Chi ² = 1 Test for overall effect: 4.3.2 RCTs O'Connor 2016 Subtotal (95% CI) Heterogeneity: Not app Test for overall effect: Total (95% CI) Heterogeneity: Chi ² = 1 Test for overall effect: Total (95% CI) Heterogeneity: Chi ² = 1 Test for overall effect: Total (95% CI) Heterogeneity: Chi ² = 1 Test for overall effect: Total (95% CI) Heterogeneity: Chi ² = 0 Test for subaroub diffect: Test for subaroub diffect: Test for subaroub diffect: Test for subaroub diffect:	Z = 1.85 rences: <u>Mean</u> 92.9 88.8 0.09, df Z = 0.81 94 plicable Z = 1.01 0.10, df Z = 1.28 rences: NDI F	PTF = 2 (P = C Chi2 = PTF SD - 11.7 (P = C) - 1	0.06) 0.06) 0.05. c 101 34 135 = 0.77 0.42) 148 148 0.31) 283 = 0.95 0.20) 0.01. (rF	$(; I^{2} = 0^{\circ})$ If = 1 (P <u>Mean</u> 91.4 88.7); I^{2} = 0^{\circ} 91.8); I^{2} = 0^{\circ} eff = 1 (F Pre	%	2). ² = <u>Tota</u> 151 13 164 151 151 315 1). ² =	0% Weight 41.8% 6.5% 48.3% 51.7% 51.7% 100.0% 0%	Std. Mean Differenc IV. Fixed, 95% 0.11 [-0.14, 0.3 0.01 [-0.63, 0.6 0.10 [-0.14, 0.3 0.12 [-0.11, 0.3 0.12 [-0.11, 0.3 0.12 [-0.11, 0.3 0.11 [-0.06, 0.2 Risk Ratio	27]	-1 -1 -1	-0.5 PT Std. Mea IV, Fiz -0.5 PT Risk	0 0.5 F DBM	1 - -	
est for overall effect: 2 est for subgroup differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022 Wadore 2017 Subtotal (95% CI) Heterogeneity: Chi ² = 1 Conon 2016 Subtotal (95% CI) Heterogeneity: Not app Test for overall effect: Total (95% CI) Heterogeneity: Chi ² = 1 Test for overall effect: Total (95% CI) Heterogeneity: Chi ² = 1 Test for subgroup differ 4. Incidence of Study or Subgroup	Z = 1.85 rences: Mean 92.9 88.8 0.09, df Z = 0.81 94 plicable Z = 1.01 0.10, df Z = 1.28 rences: NDI F	$PTF = 2 (P = C)$ $(P = C)$ $Chi^{2} = PTF$ SD $11.7 13.9$ $= 1 (P = (1 + 1))$ 18.6 $1 (P = (1 + 1))$ $(P = (1 + 1))$	0.06) 0.06) 0.05. d 101 34 135 = 0.77 0.42) 148 148 0.31) 283 = 0.95 0.020) 0.01. d FF Total	$(; I^{2} = 0)^{2}$ $If = 1 (P)^{2}$ 91.4 88.7 91.8	%	2). ² = <u>Tota</u> 151 13 164 151 315 315 1). ² = 0tal 1	0% 41.8% 6.5% 48.3% 51.7% 51.7% 100.0% 0% Wejaht	Std. Mean Differenc IV. Fixed, 95% 0.11 [-0.14, 0.3 0.01 [-0.63, 0.6 0.10 [-0.14, 0.3 0.12 [-0.11, 0.3 0.12 [-0.11, 0.3 0.12 [-0.11, 0.3 0.11 [-0.06, 0.2 Risk Ratio IV. Fixed, 95% Cl	27]	-1 -1 -1	-0.5 PT Std. Mea IV, Fix -0.5 PT Risk IV. Fixe	0 0.5 F DBM an Difference xed, 95% CI	1 • •	
Test for overall effect: 2 Test for subgroup differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022 Madore 2017 Subtotal (95% CI) Heterogeneity: Chi ² = 1 Test for overall effect: 4.3.2 RCTs O'Connor 2016 Subtotal (95% CI) Heterogeneity: Not app Test for overall effect: Total (95% CI) Heterogeneity: Chi ² = 1 Test for overall effect: Total (95% CI) Heterogeneity: Chi ² = 1 Control (95% CI) Heterogeneity: Chi ² = 1 Test for overall effect: Total (95% CI) Heterogeneity: Chi ² = 1 Stor overall effect: 4.1 Incidence of Study or Subgroup 4.4.1 RCTs	Z = 1.85 rences: Mean 92.9 88.8 0.09, df Z = 0.81 94 plicable Z = 1.01 0.10, df Z = 1.28 rences: NDI F D Ev	$PTF = 2 (P = C)$ $(P = C)$ $Chi^{2} = PTF$ SD $11.7 13.9$ $= 1 (P = (1 + C))$ 18.6 $1 (P = 1 + C)$ 18.6 $1 (P = 2 (P)$ $Chi^{2} = PTF$ $Pre-PT$	0.06) 0.06) 0.05. d 101 34 135 = 0.77 0.42) 148 148 0.31) 283 = 0.95 0.20) : 0.01. d FF Total	$(1 - 1)^{(1)}$ $(1 - 1)^{(1)}$ (1 -	%	2). ² = <u>Total</u> 151 13 164 151 315 1). ² = <u>otal 1</u>	0% Weight 41.8% 6.5% 48.3% 51.7% 51.7% 100.0% 0% Neight	Std. Mean Differenc IV. Fixed, 95% 0.11 [-0.14, 0.3 0.01 [-0.63, 0.6 0.10 [-0.14, 0.3 0.12 [-0.11, 0.3 0.12 [-0.11, 0.3 0.11 [-0.06, 0.2 Risk Ratio IV. Fixed, 95% CI	27]	-1 -1 -1	-0.5 PT Std. Mei IV, Fiz -0.5 P1 Risk _IV, Fixe	0 0.5 F DBM an Difference xed, 95% CI	1 - 1	
est for overall effect: 2 est for subgroup differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022 Wadore 2017 Subtotal (95% CI) Heterogeneity: Chi ² = 1 Co'Connor 2016 Subtotal (95% CI) Heterogeneity: Not app Test for overall effect: Total (95% CI) Heterogeneity: Chi ² = 1 Test for overall effect: Total (95% CI) Heterogeneity: Chi ² = 1 Cotal (95% CI) Cotal (95% CI)	Z = 1.85 rences: 92.9 88.8 0.09, df Z = 0.81 94 plicable Z = 1.01 0.10, df Z = 1.28 rences: NDI F D EV	$= 2 (P) = 0$ $(P = 0 C Chi^{2} = PTF SD$ $= 11.7 13.9$ $= 1 (P = 0 C Chi^{2} = 10 C Chi^{2} = $	0.06) 0.06) 0.05. d 101 34 135 = 0.77 0.42) 148 148 0.31) 283 = 0.95 0.20) 0.01. d F Total	; ² = 0 ();	% P = 0.8: DBM 14.6 17.3 % 19.1 19.1 % P = 0.9 -DBM its Tr 14	2). ² = Total 151 133 164 151 151 151 1). ² = 0tal 1	0% Weight 41.8% 6.5% 48.3% 51.7% 51.7% 100.0% Weight 00.0%	Std. Mean Differenc IV, Fixed, 95% 0.11 [-0.14, 0.3 0.01 [-0.63, 0.6 0.10 [-0.14, 0.3 0.12 [-0.11, 0.3 0.12 [-0.11, 0.3 0.11 [-0.06, 0.2 Risk Ratio IV, Fixed, 95% CI 0.87 [0.42, 1.83]	ce 6 Cl 36] 35] 33] 34] 34] 27]	-1 -1 -1	-0.5 PT Std. Mea IV. Fiz -0.5 PT Risk IV. Fixe	0 0.5 F DBM	1	
est for overall effect: 2 est for subgroup differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022 Madore 2017 Subtotal (95% CI) Heterogeneity: Chi ² = 1 Connor 2016 Subtotal (95% CI) Heterogeneity: Not app Test for overall effect: Fotal (95% CI) Heterogeneity: Chi ² = 1 Fest for overall effect: Fotal (95% CI) Heterogeneity: Chi ² = 1 Cost for subgroup differ 4. Incidence of Study or Subgroup 4.4.1 RCTs O'Connor 2016 Subtotal (95% CI)	2 = 1.85 rences: 92.9 88.8 0.09, df Z = 0.81 94 plicable Z = 1.01 0.10, df Z = 1.28 rences: NDI F D EV	$= 2 (P)^{-1} (P = 0 (P = 0)^{-1} (P = 0)^{$	0.66) 0.06) 0.05. c Total 101 34 135 = 0.77 0.42) 148 148 0.31) 283 = 0.95 0.20) 0.01. c FF Total 148 148 148 148	; r = 0.9 If = 1 (P <u>Mean</u> 91.4 88.7); ² = 0 ⁴ 91.8); ² = 0 ⁴ 91.8 (f = 1 (F Pre- Even	% P = 0.8: DBM 14.6 17.3 % 19.1 19.1 % P = 0.9 -DBM its Tr 14	2). ² = <u>Tota</u> 151 13 164 151 151 151 1). ² = <u>otal 1</u> 151 1 151	0% 41.8% 6.5% 48.3% 51.7% 51.7% 100.0% 0% Neight 00.0% 100.0%	Std. Mean Differenc IV, Fixed, 95% 0.11 [-0.14, 0.3 0.01 [-0.63, 0.6 0.10 [-0.14, 0.3 0.12 [-0.11, 0.3 0.12 [-0.11, 0.3 0.11 [-0.06, 0.2 Risk Ratio IV, Fixed, 95% CI 0.87 [0.42, 1.83] 0.87 [0.42, 1.83]	27]	-1 -1 -1	-0.5 PT Std. Mea IV, Fi2 -0.5 PT Risk IV, Fixe	0 0.5 F DBM	1	
Test for overall effect: 2 Test for subgroup differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022 Madore 2017 Subtotal (95% CI) Heterogeneity: Chi ² = 1 Test for overall effect: 4.3.2 RCTs O'Connor 2016 Subtotal (95% CI) Heterogeneity: Not appleter Total (95% CI) Heterogeneity: Chi ² = 1 Test for overall effect: Total (95% CI) Heterogeneity: Chi ² = 1 Test for overall effect: Total (95% CI) Heterogeneity: Chi ² = 0 Study or Subgroup 4.4.1 RCTs O'Connor 2016 Subtotal (95% CI) Total events	2 = 1.85 rences: 92.9 88.8 0.09, df Z = 0.81 94 plicable Z = 1.01 0.10, df Z = 1.28 rences: NDI F D EV	$= 2 (P)^{-1} (P = 0 (P = 0)^{-1} (P = 0)^{$	0.06) 0.06) 0.05. c 101 34 135 = 0.77 0.42) 148 148 0.31) 283 = 0.95 0.20) 0.01. (FF Total 148 148	; I ² = 0 if = 1 (P <u>Mean</u> 91.4 88.7); I ² = 0 ⁴ 91.8); I ² = 0 ⁴ 91.8 if = 1 (F Pre Even	% → = 0.8: SD 14.6 17.3 % 19.1 % → = 0.9 → DBM tts Tr 14 14	2). ² = Total 151 13 164 151 151 315 1). ² = 0tal 1 151 1 151 1	0% 41.8% 6.5% 48.3% 51.7% 51.7% 100.0% 0% Neight 00.0% 100.0%	Std. Mean Difference IV, Fixed, 95% 0.11 [-0.14, 0.3 0.01 [-0.63, 0.6 0.10 [-0.14, 0.3 0.12 [-0.11, 0.3 0.12 [-0.11, 0.3 0.11 [-0.06, 0.2 Risk Ratio IV, Fixed, 95% CI 0.87 [0.42, 1.83] 0.87 [0.42, 1.83]	27]	-1	-0.5 PT Std. Mea IV, Fi2 -0.5 PT Risk IV, Fixe	0 0.5 F DBM	1	
Test for overall effect: 2 Test for subaroub differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022 Madore 2017 Subtotal (95% CI) Heterogeneity: Chi ² = 1 Test for overall effect: 4.3.2 RCTs O'Connor 2016 Subtotal (95% CI) Heterogeneity: Not application Test for overall effect: Total (95% CI) Heterogeneity: Chi ² = 1 Test for overall effect: Total (95% CI) Heterogeneity: Chi ² = 1 Connor 2016 Study or Subgroup 4.4.1 RCTs O'Connor 2016 Subtotal (95% CI) Total events Heterogeneity: Not a	Z = 1.85 rences: 92.9 88.8 0.09, df Z = 0.81 94 plicable Z = 1.01 0.10, df Z = 1.28 rences: NDI F E E E E E E E E E E E E E E E E E E E	$= 2 (P)^{-1} (P = 0)^{-1} (P $	0.06) 0.06) 0.05. c 101 34 135 = 0.77 0.42) 148 148 0.31) 283 = 0.95 0.20) 0.01. c FF Total 148 148	; ² = 0	% → = 0.8: 5D 5D 5D 5D 5D 5D 5D 5D 5D 5D	2). ² = Total 151 13 164 151 151 1). ² = 0tal 1 151 1 151 1	0% Weight 41.8% 6.5% 48.3% 51.7% 51.7% 100.0% 0% Neight 00.0% 00.0%	Std. Mean Difference IV, Fixed, 95% 0.11 [-0.14, 0.3 0.01 [-0.63, 0.6 0.10 [-0.14, 0.3 0.12 [-0.11, 0.3 0.12 [-0.11, 0.3 0.11 [-0.06, 0.2 Risk Ratio IV, Fixed, 95% CI 0.87 [0.42, 1.83] 0.87 [0.42, 1.83]	27]	-1 -1 -1	-0.5 PT Std. Mea IV, Fi; -0.5 PT Risk IV, Fixe	0 0.5 F DBM	1	
Test for overall effect: 2 Test for subaroub differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022 Madore 2017 Subtotal (95% CI) Heterogeneity: Chi ² = 1 Test for overall effect: 4.3.2 RCTs O'Connor 2016 Subtotal (95% CI) Heterogeneity: Not applies Total (95% CI) Heterogeneity: Chi ² = 1 Test for overall effect: Total (95% CI) Heterogeneity: Chi ² = 1 Study or Subgroup 4.4.1 RCTs O'Connor 2016 Subtotal (95% CI) Total events Heterogeneity: Not applies Heterogeneity: Not applies Subtotal (95% CI)	2 = 1.85 rences: 92.9 88.8 0.09, df Z = 0.81 94 plicable Z = 1.01 0.10, df Z = 1.25 erences: NDI F D Ev	$= 2 (P = C Chi^{2} = PTF SD - SD $	$\begin{array}{c} = 0.52)\\ 0.06)\\ 0.05. c\\ \hline \\ 101\\ 34\\ 135\\ = 0.77\\ 0.42)\\ 148\\ 148\\ 0.31)\\ 283\\ = 0.95\\ 0.20)\\ 0.01. c\\ \mathbf{FF}\\ 148\\ 148\\ 148\\ 148\\ 148\\ 2 = 0.7\\ 0.52\\ 0.20)\\ 0.01. c\\ 148\\ 148\\ 148\\ 2 = 0.7\\ 0.52\\ 0.20\\ $	<pre>(; l² = 0.9); l² = 0.9); l² = 0.9 91.8); l² = 0.9 91.8); l² = 0.9 91.8 (df = 1 (F Pre Even </pre>	%	2). ² = Total 151 13 164 151 151 1). ² = 0tal 1 151 1 151 1	0% Weight 41.8% 6.5% 48.3% 51.7% 51.7% 100.0% 0% Neight 00.0%	Std. Mean Differenc IV, Fixed, 95% 0.11 [-0.14, 0.3 0.01 [-0.63, 0.6 0.10 [-0.14, 0.3 0.12 [-0.11, 0.3 0.12 [-0.11, 0.3 0.11 [-0.06, 0.2 Risk Ratio IV, Fixed, 95% CI 0.87 [0.42, 1.83] 0.87 [0.42, 1.83]	27]	-1	-0.5 PT Std. Mea IV. Fi; -0.5 PT Risk IV. Fixe	0 0.5 F DBM	1 - -	
Fest for overall effect: 7 Fest for subaroub differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022 Madore 2017 Subtotal (95% CI) Heterogeneity: Chi ² = 1 7 6 7 7 7 7 8 7 8 1 1 1 1 1 1 1 1	2 = 1.85 rences: 92.9 88.8 0.09, df Z = 0.81 94 plicable Z = 1.01 0.10, df Z = 1.25 rences: NDI F_{2} Ev	= 2 (P = C) $(P = C)$ Chi ² = PTF SD 11.7 13.9 $= 1 (P = C)$ 18.6 $(P = C)$ 18.6 $(P = C)$ 18.6 $(P = C)$ 18.6 $(P = C)$ 19.7 12 12 12 12 12 12 12 12 12 12 12 12 12	$\begin{array}{c} = 0.52)\\ 0.06)\\ 0.05. c\\ \hline \\ 101\\ 34\\ 135\\ = 0.77\\ 0.42)\\ 148\\ 148\\ 0.31)\\ 283\\ = 0.95\\ 0.20)\\ 0.01. c\\ \mathbf{FF}\\ \mathbf{Total}\\ 148\\ 148\\ 2 = 0.7\\ 0.52\\ 0.20)\\ 0.01. c\\ 148\\$	<pre>(; l² = 0.9); l² = 0.9); l² = 0.9 91.8); l² = 0.9 91.8); l² = 0.9 91.8 (df = 1 (F Pre Even </pre>	%	2). ² = Total 151 133 164 151 151 1). ² = 0tal 1 151 1 151 1 151 1 151 1	0% Weight 41.8% 6.5% 48.3% 51.7% 51.7% 100.0% 0% Neight 00.0%	Std. Mean Difference IV. Fixed, 95% 0.11 [-0.14, 0.3 0.01 [-0.63, 0.6 0.10 [-0.14, 0.3 0.12 [-0.11, 0.3 0.12 [-0.11, 0.3 0.12 [-0.11, 0.3 0.11 [-0.06, 0.2 Risk Ratio IV. Fixed, 95% CI 0.87 [0.42, 1.83] 0.87 [0.42, 1.83]	27]	-1	-0.5 PT Std. Mea IV, Fi; -0.5 PT Risk IV, Fixe	0 0.5 F DBM an Difference xed, 95% CI	1	
Test for overall effect: 7 Test for subgroup differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022 Madore 2017 Subtotal (95% CI) Heterogeneity: Chi ² = 1 Test for overall effect: 4.3.2 RCTs O'Connor 2016 Subtotal (95% CI) Heterogeneity: Not app Test for overall effect: Total (95% CI) Heterogeneity: Chi ² = 1 Test for overall effect: Total (95% CI) Heterogeneity: Chi ² = 0 Study or Subgroup 4.4.1 RCTs O'Connor 2016 Subtotal (95% CI) Total events Heterogeneity: Not app Total events Heterogeneity: Not app Total events Heterogeneity: Not app Total (95% CI) Total (95% CI) Total (95% CI) Total (95% CI) Total (95% CI)	Z = 1.85 rences: Mean 92.9 88.8 0.09, df Z = 0.81 94 plicable Z = 1.01 0.10, df Z = 1.26 rences: NDI F EV application ct: Z = 0	= 2 (P) = 0 (P = 0)	$\begin{array}{c} = 0.5() \\ 0.06) \\ 0.05. c \\ \hline \\ 101 \\ 34 \\ 135 \\ = 0.77 \\ 0.42) \\ 148 \\ 148 \\ 0.31) \\ 283 \\ 283 \\ 0.31) \\ 283 \\ 0.31) \\ 148 \\$	$(1 - 1)^{(2)} = 0^{(2)}$ $(1 - 1)^{(2)} = 1^{(2)}$ $(1 - 1)^{(2)} = 1^{(2)}$ $(2 - 1)^{(2)} = 1^{(2)}$ $(2 - 1)^{(2)} = 1^{(2)}$ $(2 - 1)^{(2)} = 1^{(2)}$ $(2 - 1)^{(2)} = 1^{(2)}$ $(2 - 1)^{(2)} = 1^{(2)}$ $(2 - 1)^{(2)} = 1^{(2)}$ $(2 - 1)^{(2)} = 1^{(2)}$ $(2 - 1)^{(2)} = 1^{(2)}$ $(2 - 1)^{(2)} = 1^{(2)}$ $(2 - 1)^{(2)} = 1^{(2)}$ $(2 - 1)^{(2)} = 1^{(2)}$ $(2 - 1)^{(2)} = 1^{(2)}$ $(2 - 1)^{(2)} = 1^{(2)}$ $(2 - 1)^{(2)} = 1^{(2)}$ $(2 - 1)^{(2)} = 1^{(2)}$ $(2 - 1)^{(2)} = 1^{(2)}$ $(2 - 1)^{(2)} = 1^{(2)}$	%	2). ² = Total 151 13 164 151 151 1). ² = 151 151 151 151 151 151 151	0% Weight 41.8% 6.5% 48.3% 51.7% 51.7% 100.0% 0% Neight 00.0% 100.0%	Std. Mean Differenc IV. Fixed, 95% 0.11 [-0.14, 0.3 0.01 [-0.63, 0.6 0.10 [-0.14, 0.3 0.12 [-0.11, 0.3 0.12 [-0.11, 0.3 0.11 [-0.06, 0.2 Risk Ratio IV. Fixed, 95% CI 0.87 [0.42, 1.83] 0.87 [0.42, 1.83]	27]	-1	-0.5 PT Std. Mea IV, Fi; -0.5 PT Risk IV. Fixe	0 0.5 F DBM an Difference xed, 95% CI	1	
Test for overall effect: 2 Test for subgroup differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022 Madore 2017 Subtotal (95% CI) Heterogeneity: Chi ² = 1 Test for overall effect: 4.3.2 RCTs 0'Connor 2016 Subtotal (95% CI) Heterogeneity: Not app Test for overall effect: Total (95% CI) Heterogeneity: Chi ² = 1 Test for subgroup differ 4.4.1 RCTs 0'Connor 2016 Subtotal (95% CI) Total events Heterogeneity: Not a Subtotal (95% CI) Total events Heterogeneity: Not a Test for overall effect: 1.5.1 RCTs 0'Connor 2016 Subtotal (95% CI) Total events Heterogeneity: Not a Test for overall effect: 1.5.1 RCTs 0'Connor 2016 Subtotal (95% CI) Total events Heterogeneity: Not a	Z = 1.85 rences: <u>Mean</u> 92.9 88.8 0.09, df Z = 0.81 94 plicable Z = 1.01 0.10, df Z = 1.25 rences: NDI F E C C C C C C C C	= 2 (P) = 0 (P = 0 Chi ² = PTF SD 11.7 13.9 = 1 (P = (18.6 1 (P = (18.6 1 (P = (19.6 19.6 1 (P = (12.6 12 12 12 12 12 12 12 12 12 12 12 12 12	$\begin{array}{c} = 0.5(2) \\ 0.06) \\ 0.05. c \\ \hline 101 \\ 34 \\ 135 \\ = 0.77 \\ 0.42) \\ 148 \\ 148 \\ 0.31) \\ 283 \\ = 0.95 \\ 0.20) \\ c 0.01. c \\ 0.01. c \\ 148 \\ 1$	(; r = 0.9 if = 1 (P <u>Mean</u> 91.4 88.7); ² = 0 ⁰ 91.8); ² = 0 ⁰ 91.8 (i); ² = 0 ⁰ 91.8 (i); ² = 0 ⁰ 91.8 (i); ² = 0 ⁰ 91.8 (i); ² = 0 ⁰ (i); ² = 0	%	2). $ ^2 = \frac{1}{151}$ 151 153 164 151 315 1). $ ^2 = \frac{1}{151}$ 151 151 151	0% 41.8% 6.5% 48.3% 51.7% 51.7% 100.0% 0% Weight 00.0% 100.0%	Std. Mean Differenc IV. Fixed, 95% 0.11 [-0.14, 0.3 0.01 [-0.63, 0.6 0.10 [-0.14, 0.3 0.12 [-0.11, 0.3 0.12 [-0.11, 0.3 0.11 [-0.06, 0.2 Risk Ratio IV. Fixed, 95% CI 0.87 [0.42, 1.83] 0.87 [0.42, 1.83]	27]	-1 -1 -1	-0.5 PT Std. Mea IV, Fi) -0.5 PT -0.5 PT Risk IV. Fixe	0 0.5 F DBM	1	
est for overall effect: 2 est for subgroup differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022 Wadore 2017 Subtotal (95% Cl) Heterogeneity: Chi ² = 1 Fest for overall effect: 4.3.2 RCTs D'Connor 2016 Subtotal (95% Cl) Heterogeneity: Not app Fest for overall effect: Fotal (95% Cl) Heterogeneity: Chi ² = 1 Fest for subgroup diffe 4. Incidence of Study or Subgroup 4.4.1 RCTs D'Connor 2016 Subtotal (95% Cl) Total events Heterogeneity: Not a Test for overall effect: Total (95% Cl) Total events Heterogeneity: Not a Test for overall effect Total (95% Cl) Total events Heterogeneity: Not a Test for overall effect	Z = 1.85 rences: $Q2.9$ 88.8 $Q2.9$ 94 94 94 94 94 94 94 9	$= 2 (P)^{-1} (P = 0)^{-1} (P $	$\begin{array}{c} = 0.5(2) \\ 0.06) \\ 0.05. c \\ \hline 101 \\ 34 \\ 135 \\ = 0.77 \\ 0.42) \\ 148 \\ 148 \\ 0.31) \\ 283 \\ 148 \\ 0.31) \\ 283 \\ 148 \\ 148 \\ 148 \\ 148 \\ 148 \\ 148 \\ 148 \\ 148 \\ 148 \\ 2 = 0.7 \\ 148 \\ 148 \\ 148 \\ 148 \\ 148 \\ 148 \\ 148 \\ 148 \\ 148 \\ 148 \\ 148 \\ 148 \\ 148 \\ 148 \\ 148 $	$(1 - 1)^{2}$ $(1 - 1)^{2}$ (1 -	%	2). $ ^2 = \frac{1}{151}$ 151 153 164 151 315 1). $ ^2 = \frac{1}{151}$ 151 151 151	0% 41.8% 6.5% 48.3% 51.7% 51.7% 100.0% 0% Weight 00.0% 100.0%	Std. Mean Differenc IV. Fixed, 95% 0.11 [-0.14, 0.3 0.01 [-0.63, 0.6 0.10 [-0.14, 0.3 0.12 [-0.11, 0.3 0.12 [-0.11, 0.3 0.11 [-0.06, 0.2 Risk Ratio IV. Fixed, 95% CI 0.87 [0.42, 1.83] 0.87 [0.42, 1.83]	27] 0.1 0	-1 -1 -1	-0.5 PT Std. Mea IV, Fi) -0.5 PT Risk IV. Fixe	0 0.5 F DBM an Differenc: xed, 95% Cl 0 0.5 FF DBM c Ratio cd, 95% Cl	1	
Test for overall effect: 2 Test for subgroup differ 3. Motor Scores Study or Subgroup 4.3.1 Cohort Studies Hair 2022 Wadore 2017 Subtotal (95% CI) Heterogeneity: Chi ² = 1 Test for overall effect: 4.3.2 RCTs D'Connor 2016 Subtotal (95% CI) Heterogeneity: Not app Test for overall effect: Total (95% CI) Heterogeneity: Chi ² = 1 Test for overall effect: Total (95% CI) Heterogeneity: Chi ² = 1 Connor 2016 Subtotal (95% CI) Heterogeneity: Chi ² = 1 Cost for subgroup diffect 4. Incidence of Study or Subgroup D'Connor 2016 Subtotal (95% CI) Total events Heterogeneity: Not a Test for overall effect Total (95% CI) Total events Heterogeneity: Not a Test for overall effect	Z = 1.85 $Z = 1.85$ $P = 2.9$ 88.8 $0.09, df$ $Z = 0.81$ 94 94 $P = 0.81$ $Q = 1.25$ $Z = 1.01$ $0.10, df$ $Z = 1.25$ $Z = 1.25$ $D = 2$ $Z = 1.01$ $Q = 1.25$ $Z = 1.25$ $Q = 1.2$	$ = 2 (P) $ $ (P = C) Chi^{2} = PTF SD $ $ = 1 (P) $	$\begin{array}{c} = 0.52 \\ 0.06 \\ 0.05. c \\ \hline \\ 101 \\ 34 \\ 135 \\ = 0.77 \\ 0.42 \\ 148 \\ 148 \\ 0.31 \\ \hline \\ 283 \\ = 0.95 \\ 0.020 \\ \hline \\ 0.011. c \\ 148 \\ 148 \\ 148 \\ \hline \\ 2 = 0.7 \\ \hline \\ 148 \\ 148 \\ 148 \\ \hline \\ 2 = 0.7 \\ 148 \\ 148 \\ \hline \\ 2 = 0.7 \\ 148 \\ 148 \\ 148 \\ \hline \\ 2 = 0.7 \\ 148 \\ 148 \\ 148 \\ \hline \\ 2 = 0.7 \\ 148 \\ 148 \\ 148 \\ \hline \\ 2 = 0.7 \\ 148$	<pre>(; r = 0.%) (; r = 0.%) (; r = 1 (P)</pre>	% P = 0.8: DBM 14.6 17.3 % 19.1 19.1 % P = 0.9 -DBM -DBM 14 14 14	2). ² = <u>Total</u> 151 13 164 151 151 151 10. ² = 0tal 1 151 1 151 1 151 1	0% 41.8% 6.5% 48.3% 51.7% 51.7% 100.0% 0% Neight 00.0% 00.0%	Std. Mean Differenc IV, Fixed, 95% 0.11 [-0.14, 0.3 0.01 [-0.63, 0.6 0.10 [-0.14, 0.3 0.12 [-0.11, 0.3 0.12 [-0.11, 0.3 0.11 [-0.06, 0.2 Risk Ratio IV. Fixed, 95% CI 0.87 [0.42, 1.83] 0.87 [0.42, 1.83]	ce 6 Cl 36] 36] 33] 34] 34] 27] 0.1 0	-1 -1 -1	-0.5 PT Std. Mea IV, Fiz -0.5 PT Risk IV, Fixe 0.5 PTe-PTF	0 0.5 F DBM	1	

preterm infants frequently face complications such as bronchopulmonary dysplasia (BPD), intraventricular hemorrhage (IVH), necrotizing enterocolitis (NEC), and long-term NDOs (58). While the prevalence of preterm births in China highlights the need for research on breastfeeding and NDOs, the lack of local studies presents an important area for future exploration.

The review did not encompass an evaluation of the effects of fortifiers; consequently, the existing evidence is insufficient to draw definitive conclusions regarding their impact on NDOs in preterm infants. Additionally, our search was confined to literature published in English and Chinese, which may have led to the omission of relevant studies. Furthermore, while we intended to stratify the analyses based on varying income settings, we identified no studies from low-income countries and only one (45) from a middle-income country. This limited geographic and economic representation has restricted our ability to make meaningful subgroup comparisons across income levels. Consequently, the findings presented here primarily represent contemporary practices in neonatal intensive care units (NICUs), as the majority of studies included in the meta-analysis originated from developed nations.

Simultaneously, we evaluated the quality of the included studies and found that most were observational, with only one RCT. As a result, the overall quality of evidence was generally weak. Methodological limitations were prevalent, including insufficient control of confounding variables (45, 47), small sample sizes (47, 52, 55), selection bias (44, 47, 49, 50, 54, 56, 57), and high rates of attrition (45, 47, 52). Many studies recruited infants born before 2010 (31, 36, 45–55, 57), and only two reported outcomes beyond 24 months (31, 47), making it difficult to assess the long-term effects of breastfeeding on NDOs in preterm infants. Additionally, some studies included infants with a GA of 32 weeks or more and/or a BW above 1,500 g (47, 50, 53, 55–57). None of these studies reported results stratified by GA and BW; therefore, the findings cannot be generalized to all preterm infants, particularly the very preterm infants (<1,500 g), who represent a more vulnerable subset of our population of interest.

Sources of bias in any meta-analysis include the selection and heterogeneity of the included studies. A specific limitation of our systematic review and meta-analysis concerns the date selection. Although our search criteria excluded studies published before 2000, some included studies relied on retrospective data from before 2000, potentially reflecting outdated practices and contributing to heterogeneity. This temporal variation complicates the synthesis of findings and may impact the applicability of conclusions to current clinical practices. While our inclusion criteria specified our population and outcomes of interest, we encountered heterogeneity, with some studies choosing to study only very preterm infants (<1,000g or < 1,500 g), a more vulnerable subset of our population of interest, which may limit applicability. Additionally, combining studies with endpoint classifications ranging from 6 months to 7 years was challenging, with 58.8% of assessments conducted at 18 to 24 months. The absence of standardized endpoints for evaluating NDOs in preterm infants further complicated direct comparisons. Furthermore, while most studies reported breastfeeding rates, the methods used to quantify milk intake (e.g., "higher" vs. "lower") differed significantly, particularly when comparing groups such as "Any-BF" vs. "Never-BF" or "Pre-BF" vs. "Pre-PTF." The range of breastfeeding exposure varied from exclusive breastfeeding to as little as 9.6% of total intake, or it was inconsistently measured across studies. Given this variability, there is a pressing need for standardized neurodevelopmental assessment tools with long-term predictive validity, as well as further research into the complex relationship between breastfeeding and NDOs in preterm infants, based on more precise and consistent measurements of breastfeeding intake.

The majority of studies included in this review employed a rigorous approach to control for potential confounding variables, including neonatal complications, parental IQ, and socioeconomic differences. However, two studies lacked sufficient detail in defining these factors (45, 47). The methods employed to adjust for these covariates exhibited considerable variation across the included studies. The majority of the evidence reviewed is derived from observational studies, with only one randomized controlled trial (RCT) included, which may introduce a risk of bias. The objective of this review was to provide a comprehensive synthesis of the available evidence, and thus both RCTs and observational studies were included. The GRADE system was utilized to evaluate the certainty of the evidence, incorporating study design into the assessment. However, a considerable number of the studies had relatively small sample sizes, which complicated the interpretation of the evidence, particularly when comparing data from both RCTs and observational studies, where the observed effects may not align. To address potential sources of bias, we conducted subgroup analyses based on GA, BW, assessment time points, and maternal education/IQ, utilizing random-effects models to account for variability. A funnel plot and Egger's test were employed to detect potential publication bias. The results indicated the presence of bias in one analysis, which resulted in a downgrade in the certainty of the evidence. This highlights the need for high-quality, large-scale, long-term studies that stratify results by GA and BW to more accurately investigate the relationship between breastfeeding and NDOs in preterm infants.

4.3 Mechanisms of the association between BF and NDOs

Breastfeeding plays a crucial role in the long-term neurodevelopment of preterm infants, with its benefits supported by evidence across multiple mechanisms. One critical aspect is the enhancement of maternal bonding through skin-to-skin contact and breastfeeding (59-62). This bonding not only strengthens the mother-infant attachment but also fosters emotional and cognitive development (63), often linked to increased maternal sensitivity and engagement in cognitively stimulating activities such as verbal interactions and sensory play (62). Furthermore, the nutritional composition of human milk is indispensable for both physical and neurological development in preterm infants (64). Rich in essential nutrients, human milk contains long-chain polyunsaturated fatty acids (PUFAs) (18, 65), particularly DHA, which are vital for brain development, contributing to synaptogenesis and myelination-critical processes in cognitive and visual development (66, 67). Moreover, the role of human milk oligosaccharides (HMOs) in neurodevelopment cannot be understated (68). HMOs foster a healthy gut microbiome, which in turn influences the gut-brain axis-an area of increasing interest in neuroscience. This connection highlights the interplay between nutrition and neurological development, suggesting that both the physical components of breast milk and the behavioral interactions surrounding breastfeeding are critical. Additionally, recent studies underscore the importance of immunological factors in breast milk, particularly immunoglobulin A (IgA), which protects the developing brain from neuroinflammation, a crucial element in preventing cognitive impairments (69). In summary, the synergistic effects of these components—enhanced maternal bonding, optimal nutrition, and immune protection—are especially critical during the brain's periods of plasticity. During these critical periods, the combined influence of these factors can have lasting positive impacts on neurodevelopment, underscoring the importance of breastfeeding in the early stages of life.

4.4 Findings from other reviews

A previous systematic review evaluated eight observational studies involving 1,560 preterm infants and provided very low-certainty evidence regarding the impact of formula feeding versus breastfeeding NDOs (70). It concluded that breastfeeding had limited or no significant impact on cognitive and language neurodevelopment compared to formula feeding. Our updated review, which incorporated eight additional studies and expanded the participant pool to 3,982 infants, revealed altered effects on cognitive outcomes as of 2022 (70). However, the impact on motor and language development remained unchanged, and the overall certainty of the evidence did not improve.

Two recent Cochrane reviews (71, 72) and three non-Cochrane reviews (20, 73, 74) have further explored the impact of breastfeeding on NDOs in preterm infants. For instance, Brown et al. (72) conducted a Cochrane review but identified no relevant randomized controlled trials (RCTs) comparing the developmental outcomes between formula-fed and breastfed infants. Similarly, our review, despite utilizing a comprehensive search strategy, identified only one cohort study conducted by Were et al. (45), which suggested that extremely low birth weight (ELBW) infants fed formula exhibited better developmental outcomes at two years of age compared to those exclusively breastfed. However, the authors noted that NDOs in ELBW infants could be influenced by uncontrolled confounders, such as maternal health and socioeconomic factors. Furthermore, the study did not specify whether breast milk was routinely fortified, raising the possibility that inadequate nutrient intake from unfortified breast milk may have contributed to these findings. Research demonstrates that fortified breast milk can result in developmental outcomes comparable to those seen with preterm formula (75-77). This supports the hypothesis that insufficient nutrient supply disproportionately affects the most vulnerable infants-those with the highest nutritional demands—during the critical period of neonatal hospitalization (78).

A separate Cochrane review from 2019 provided moderatecertainty evidence that formula feeding promotes better weight gain and growth compared to DBM (71). However, these trial data did not indicate any long-term neurodevelopmental benefits. It is important to note that some studies included in these reviews focused on NDOs from the 1990s, making their relevance to contemporary clinical practice limited. As clinical protocols have advanced, the generalizability of these findings has decreased, leading to the exclusion of older studies from our review. Two cohort studies were identified: a retrospective cohort study (n=252) (54) and a prospective cohort study (n=81) (52). Both studies found cognitive improvements among preterm infants receiving donor breast milk; however, no significant effects were observed in language development, motor skills, or neurological function. In contrast, a randomized controlled trial by O'Connor et al. (51), consistent with Quigley et al. (71) review, found no benefits of donor breast milk in these outcomes for preterm infants. Thus, if donor milk is used in a setting with high maternal breast milk provision, it should not be regarded as a standalone intervention for improving NDOs. Several factors may explain the lack of observed improvements. Firstly, existing literature suggests a dose-dependent relationship between breastfeeding volume and NDOs in VLBW infants (46, 50, 79). While the studies included in our analysis adjusted for breast milk intake, it remains possible that the level of supplementation was insufficient to yield an observable effect on NDOs. Secondly, maternal breast milk and donor milk differ in nutrient and bioactive component composition (80). Pasteurization of donor milk may alter key bioactive components, potentially affecting neurodevelopment (80, 81). Lastly, donor milk is typically term milk, which may not meet the specific nutritional needs of preterm infants.

In addition to the Cochrane reviews, several non-Cochrane reviews have examined various outcomes, including in-hospital growth and neurodevelopment. A 2017 narrative review (74) suggested a modest protective effect of breastfeeding on neurodevelopment, while acknowledging numerous confounding variables such as neonatal complications, parental IQ, and socioeconomic status. Our current review re-examined six highquality studies from this review and found that most had adjusted for major confounders, with only two exceptions (45, 47). However, it is important to recognize that confounding variables were not consistently controlled for across studies, which introduces the risk of publication bias and heterogeneity. To address this, we conducted subgroup analyses based on whether the key confounder-maternal education level or IQ-was controlled for, and found no significant impact on the primary outcomes. Consequently, promoting and supporting breastfeeding remains a critical public health goal. A metaanalysis by Miller et al. (73) sought to differentiate the effects of breastfeeding and preterm formula on NDOs but found insufficient evidence to draw definitive conclusions on cognitive and motor development. Our updated analysis, which incorporates more recent studies, consistently shows that any breastfeeding is associated with improved cognitive development and reduced neurodevelopmental impairment compared to exclusive formula feeding. However, no significant improvements were observed in predominantly breastfed preterm infants compared to those fed formula, which is consistent with the findings of Miller et al. (73). This divergence from conventional understanding may be attributable to differences in study populations, variations in breastfeeding intake and assessment points, and methodological inconsistencies across the studies included in our review. These findings underscore the need for more highquality research, especially randomized controlled trials or welldesigned cohort studies, to control for confounders and provide more reliable evidence.

Furthermore, a 2022 review by Hernandez-Luengo et al. focused on motor development and found that infants who were exclusively or ever breastfed had superior motor development compared to those never breastfed (20). These findings align with some outcomes in our review, suggesting that any breastfeeding positively impacts motor development in ELBW infants. However, it is crucial to acknowledge that the study conducted by Hernandez-Luengo et al. examined the influence of breast milk on motor assessments in individuals under the age of 18 years. Consequently, their findings may not entirely align with those of Miller et al.'s previous analysis and our results, which focused on a distinct group of preterm infants (73). Further research is necessary to validate whether breastfeeding during the neonatal period enhances long-term motor developmental outcomes in preterm infants, and to explore the effects of variables such as GA, BW, and breast milk fortification.

4.5 Implications for practice

This systematic review and meta-analysis provide robust support for current breastfeeding recommendations and underscore the critical role of feeding practices in enhancing NDOs among preterm infants. Given the significant cognitive and behavioral challenges commonly experienced by this population, the promotion of breastfeeding is of paramount importance. Notably, our analysis demonstrates a clear association between reduced breastfeeding rates and an elevated risk of suboptimal neurodevelopment, a relationship that is increasingly concerning in the context of rising preterm birth rates. As breastfeeding represents a modifiable factor, it is essential to educate parents on its neurodevelopmental benefits and to actively promote strategies that encourage increased breastfeeding rates, which may serve to mitigate the associated risks. Furthermore, in clinical settings where maternal breast milk is available in sufficient quantities, DHM should be regarded as a complementary intervention rather than a primary or standalone strategy for optimizing NDOs.

4.6 Implications for research

Further epidemiological research is critical to elucidate the relationship between breastfeeding and NDOs in preterm infants. Numerous confounding factors, including maternal age, education level, socioeconomic status, and the home environment, exert a significant influence on NDOs. However, inconsistent control of these variables across studies has contributed to a lack of consensus in the current body of evidence. Given the ethical challenges that limit the feasibility of conducting randomized controlled trials on breastfeeding, it is imperative to rigorously control for confounders and employ validated assessment tools to ensure the reliability and validity of findings in long-term prospective cohort studies conducted in real-world settings. This approach is particularly important in regions with elevated rates of preterm births, such as China. Addressing these methodological complexities will be a central focus of our forthcoming research.

5 Conclusion

In conclusion, this study advances the understanding of breastfeeding's impact on NDOs in preterm infants. Despite inconsistencies in existing research, our findings indicate that breastfeeding, even in small amounts, may positively influence cognitive development in this population. Further studies are needed to clarify if DHM shows similar neurodevelopmental benefits, as these studies were not powered to study this outcome adequately. The certainty of the evidence was low, and the small effect sizes limit the clinical relevance of the findings. Further research is needed to confirm these results and explore the underlying mechanisms. This study underscores the importance of promoting breastfeeding to optimize NDOs in preterm infants.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding authors.

Author contributions

RZ: Funding acquisition, Writing – original draft, Writing – review & editing, Methodology. EY: Methodology, Writing – review & editing, Resources, Writing – original draft. XW: Methodology, Writing – original draft, Writing – review & editing. HQ: Methodology, Writing – review & editing, Formal analysis, Writing – original draft. YG: Formal analysis, Methodology, Writing – review & editing, Data curation, Writing – original draft. XG: Data curation, Formal analysis, Methodology, Writing – review & editing, Writing – original draft. ZY: Conceptualization, Supervision, Writing – original draft, Writing – review & editing, Project administration. JC: Conceptualization, Supervision, Writing – original draft, Writing – review & editing, Project administration.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This review was funded by the Shenzhen Science and Technology Innovation Commission Fund, grant number JCYJ20230807152302005.

Acknowledgments

We thank Dr. Na Zhang from Xiangya Hospital, Central South University, for her essential support in data retrieval and literature screening, which was vital to the completion of this study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2024.1401250/ full#supplementary-material

References

1. World Health Organization. Born too soon: decade of action on preterm birth World Health Organization (2023) Available at: https://www.who.int/publications/i/ item/9789240073890.

2. Ohuma EO, Moller AB, Bradley E, Chakwera S, Hussain-Alkhateeb L, Lewin A, et al. National, regional, and global estimates of preterm birth in 2020, with trends from 2010: a systematic analysis. *Lancet*. (2023) 402:1261–71. doi: 10.1016/S0140-6736(23)00878-4

3. Perin J, Mulick A, Yeung D, Villavicencio F, Lopez G, Strong KL, et al. Global, regional, and national causes of under-5 mortality in 2000–19: an updated systematic analysis with implications for the sustainable development goals. *Lancet Child Adolesc Health*. (2022) 6:106–15. doi: 10.1016/S2352-4642(21)00311-4

 Sebastian E, Bykersma C, Eggleston A, Eddy KE, Chim ST, Zahroh RI, et al. Costeffectiveness of antenatal corticosteroids and tocolytic agents in the management of preterm birth: a systematic review. *EClinicalMedicine*. (2022) 49:101496. doi: 10.1016/j. eclinm.2022.101496

5. Cao Y, Jiang S, Sun J, Hei M, Wang L, Zhang H, et al. Assessment of neonatal intensive care unit practices, morbidity, and mortality among very preterm infants in China. *JAMA Netw Open*. (2021) 4:e2118904. doi: 10.1001/jamanetworkopen.2021.18904

6. Ramaswamy VV, Abiramalatha T, Bandyopadhyay T, Shaik NB, Bandiya P, Nanda D, et al. ELBW and ELGAN outcomes in developing nations-systematic review and meta-analysis. *PLoS One*. (2021) 16:e0255352. doi: 10.1371/journal.pone.0255352

7. Newnham JP, Schilling C, Petrou S, Morris JM, Wallace EM, Brown K, et al. The health and educational costs of preterm birth to 18 years of age in Australia. *Aust N Z J Obstet Gynaecol.* (2022) 62:55–61. doi: 10.1111/ajo.13405

8. World Health Organization WHO recommendations for care of the preterm or low-birth-weight infant. Geneva: World Health Organization; (2022). (WHO guidelines approved by the guidelines review committee). Available at: http://www.ncbi.nlm.nih. gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_ uids=36449655&query_hl=1%.

9. Boquien CY. Human Milk: an ideal food for nutrition of preterm newborn. *Front Pediatr.* (2018) 6:295. doi: 10.3389/fped.2018.00295

10. Victora CG, Bahl R, Barros AJ, Franca GV, Horton S, Krasevec J, et al. Lancet breastfeeding series G. Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect. *Lancet*. (2016) 387:475–90. doi: 10.1016/S0140-6736(15)01024-7

11. Narayanan I, Prakash K, Murthy NS, Gujral VV. Randomised controlled trial of effect of raw and holder pasteurised human milk and of formula supplements on incidence of neonatal infection. *Lancet.* (1984) 2:1111–3. doi: 10.1016/s0140-6736(84)91554-x

12. Kramer MS, Kakuma R. Optimal duration of exclusive breastfeeding. *Cochrane Database Syst Rev.* (2012) 2012:CD003517. doi: 10.1002/14651858.CD003517.pub2

13. World Health Organization. Guideline: protecting, promoting and supporting breastfeeding in facilities providing maternity and newborn services World Health Organization (2017).

14. Subspecialty Group of Child Health Care, the Society of Pediatrics, Chinese Medical Association; Chinese Society of Perinatal Medicine; Chinese Nutrition Society Maternal and Child Nutrition Branch. Guideline for breastfeeding promotion strategies (2018). *Zhonghua Er Ke Za Zhi.* (2018) 56:261–6. doi: 10.3760/cma.jissn.0578-1310.2018.04.005

15. Martin RM, Kramer MS, Patel R, Rifas-Shiman SL, Thompson J, Yang S, et al. Effects of promoting long-term, exclusive breastfeeding on adolescent adiposity, blood pressure, and growth trajectories: a secondary analysis of a randomized clinical trial. *JAMA Pediatr.* (2017) 171:e170698. doi: 10.1001/jamapediatrics.2017.0698

16. Horta BL, Loret de Mola C, Victora CG. Breastfeeding and intelligence: a systematic review and meta-analysis. *Acta Paediatr.* (2015) 104:14–9. doi: 10.1111/apa.13139

17. Mortensen EL, Michaelsen KF, Sanders SA, Reinisch JM. The association between duration of breastfeeding and adult intelligence. *JAMA*. (2002) 287:2365–71. doi: 10.1001/jama.287.18.2365

18. Pang WW, Tan PT, Cai S, Fok D, Chua MC, Lim SB, et al. Nutrients or nursing? Understanding how breast milk feeding affects child cognition. *Eur J Nutr.* (2020) 59:609–19. doi: 10.1007/s00394-019-01929-2

19. Ghassabian A, Sundaram R, Bell E, Bello SC, Kus C, Yeung E. Gross motor milestones and subsequent development. *Pediatrics*. (2016) 138:e20154372. doi: 10.1542/ peds.2015-4372

20. Hernandez-Luengo M, Alvarez-Bueno C, Martinez-Hortelano JA, Cavero-Redondo I, Martinez-Vizcaino V, Notario-Pacheco B. The relationship between breastfeeding and motor development in children: a systematic review and metaanalysis. *Nutr Rev.* (2022) 80:1827–35. doi: 10.1093/nutrit/nuac013

21. Isaacs EB, Fischl BR, Quinn BT, Chong WK, Gadian DG, Lucas A. Impact of breast milk on intelligence quotient, brain size, and white matter development. *Pediatr Res.* (2010) 67:357–62. doi: 10.1203/PDR.0b013e3181d026da

22. Kafouri S, Kramer M, Leonard G, Perron M, Pike B, Richer L, et al. Breastfeeding and brain structure in adolescence. *Int J Epidemiol.* (2013) 42:150–9. doi: 10.1093/ ije/dys172

23. Zhang Y, Deng Q, Wang J, Wang H, Li Q, Zhu B, et al. The impact of breast milk feeding on early brain development in preterm infants in China: an observational study. *PLoS One.* (2022) 17:e0272125. doi: 10.1371/journal.pone.0272125

24. Prentice AM. Breastfeeding in the modern world. Ann Nutr Metab. (2022) 78:29–38. doi: 10.1159/000524354

25. Duan Y, Yang Z, Lai J, Yu D, Chang S, Pang X, et al. Exclusive breastfeeding rate and complementary feeding indicators in China: a national representative survey in 2013. *Nutrients*. (2018) 10:249. doi: 10.3390/nu10020249

26. Li Z, Jia Y, Parshley I, Zhang Y, Wang J, Long Q. Current prevalence, changes, and determinants of breastfeeding practice in China: data from cross-sectional national household health services surveys in 2013 and 2018. *Int Breastfeed J.* (2023) 18:40. doi: 10.1186/s13006-023-00572-2

27. Azad MB, Vehling L, Chan D, Klopp A, Nickel NC, McGavock JM, et al. Infant feeding and weight gain: separating breast Milk from breastfeeding and formula from food. *Pediatrics*. (2018) 142:e20181092. doi: 10.1542/peds.2018-1092

28. Boone KM, Geraghty SR, Keim SA. Feeding at the breast and expressed Milk feeding: associations with otitis media and diarrhea in infants. *J Pediatr.* (2016) 174:118–25. doi: 10.1016/j.jpeds.2016.04.006

29. Cusick SE, Georgieff MK. The role of nutrition in brain development: the Golden opportunity of the "first 1000 days". *J Pediatr.* (2016) 175:16–21. doi: 10.1016/j. jpeds.2016.05.013

30. Smith MM, Durkin M, Hinton VJ, Bellinger D, Kuhn L. Influence of breastfeeding on cognitive outcomes at age 6–8 years: follow-up of very low birth weight infants. *Am J Epidemiol.* (2003) 158:1075–82. doi: 10.1093/aje/kwg257

31. Belfort MB, Anderson PJ, Nowak VA, Lee KJ, Molesworth C, Thompson DK, et al. Breast Milk feeding, brain development, and neurocognitive outcomes: a 7-year longitudinal study in infants born at less than 30 Weeks' gestation. *J Pediatr.* (2016) 177:133–139.e1. doi: 10.1016/j.jpeds.2016.06.045

32. Ericson J, Ahlsson F, Wackernagel D, Wilson E. Equally good neurological, growth, and health outcomes up to 6 years of age in moderately preterm infants who received exclusive vs. fortified breast Milk-a longitudinal cohort study. *Nutrients*. (2023) 15:2318. doi: 10.3390/nu15102318

33. Rodrigues C, Zeitlin J, Zemlin M, Wilson E, Pedersen P, Barros H, et al. Effective perinatal intensive Care in Europe Research G. Never-breastfed children face a higher risk of suboptimal cognition at 2 years of corrected age: a multinational cohort of very preterm children. *Matern Child Nutr.* (2022) 18:e13347. doi: 10.1111/mcn.13347

34. Ruys CA, Bröring T, van Schie PEM, van de Lagemaat M, Rotteveel J, Finken MJJ, et al. Neurodevelopment of children born very preterm and/or with a very low birth weight: 8-year follow-up of a nutritional RCT. *Clin Nutr ESPEN*. (2019) 30:190–8. doi: 10.1016/j.clnesp.2018.12.083

35. Britton JR, Britton HL, Gronwaldt V. Breastfeeding, sensitivity, and attachment. *Pediatrics*. (2006) 118:e1436-43. doi: 10.1542/peds.2005-2916

36. Furman L, Wilson-Costello D, Friedman H, Taylor HG, Minich N, Hack M. The effect of neonatal maternal milk feeding on the neurodevelopmental outcome of very low birth weight infants. *J Dev Behav Pediatr.* (2004) 25:247–53. doi: 10.1097/00004703-200408000-00004

37. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. (2021) 372:n71. doi: 10.1136/bmj.n71

38. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Metaanalysis of observational studies in epidemiology: a proposal for reporting. Metaanalysis of observational studies in epidemiology (MOOSE) group. *JAMA*. (2000) 283:2008–12. doi: 10.1001/jama.283.15.2008

39. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. (2011) 343:d5928. doi: 10.1136/bmj.d5928

40. Wells GA, Shea BO, Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute (2019).

41. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. *BMJ*. (2001) 323:101–5. doi: 10.1136/bmj.323.7304.101

42. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol.* (2011) 64:383–94. doi: 10.1016/j.jclinepi.2010.04.026

43. Schünemann H, Brożek J, Guyatt G, Oxman A. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013 The GRADE Working Group (2013). 2021 p. Available at: https://gdt.gradepro.org/app/handbook/handbook.html

44. Yackobovitch-Gavan M, Atia Shmueli S, Morag I. Neurodevelopmental outcomes among infants born preterm fed with Mother's own Milk: a comparison of singletons and twins. *J Pediatr.* (2023) 259:113484. doi: 10.1016/j.jpeds.2023.113484

45. Were FN, Bwibo NO. Two year neurological outcomes of very low birth weight infants. *East Afr Med J.* (2006) 83:243–9. doi: 10.4314/eamj.v83i5.9429

46. Vohr BR, Poindexter BB, Dusick AM, McKinley LT, Wright LL, Langer JC, et al. Beneficial effects of breast milk in the neonatal intensive care unit on the developmental outcome of extremely low birth weight infants at 18 months of age. *Pediatrics*. (2006) 118:E115–23. doi: 10.1542/peds.2005-2382

47. Tanaka K, Kon N, Ohkawa N, Yoshikawa N, Shimizu T. Does breastfeeding in the neonatal period influence the cognitive function of very-low-birth-weight infants at 5 years of age? *Brain and Development.* (2009) 31:288–93. doi: 10.1016/j. braindev.2008.05.011

48. Pinelli J, Saigal S, Atkinson SA. Effect of breastmilk consumption on neurodevelopmental outcomes at 6 and 12 months of age in VLBW infants. Adv Neonatal Care. (2003) 3:76–87. doi: 10.1053/adnc.2003.50017

49. Patra K, Hamilton M, Johnson TJ, Greene M, Dabrowski E, Meier PP, et al. NICU human Milk dose and 20-month neurodevelopmental outcome in very low birth weight infants. *Neonatology*. (2017) 112:330–6. doi: 10.1159/000475834

50. O'Connor DL, Jacobs J, Hall R, Adamkin D, Auestad N, Castillo M, et al. Growth and development of premature infants fed predominantly human milk, predominantly premature infant formula, or a combination of human milk and premature formula. *J Pediatr Gastroenterol Nutr.* (2003) 37:437–46. doi: 10.1097/00005176-200310000-00008

51. O'Connor DL, Gibbins S, Kiss A, Bando N, Brennan-Donnan J, Ng E, et al. Effect of supplemental donor human Milk compared with preterm formula on neurodevelopment of very low-birth-weight infants at 18 months: a randomized clinical trial. *JAMA*. (2016) 316:1897–905. doi: 10.1001/jama.2016.16144

52. Madore LS, Bora S, Erdei C, Jumani T, Dengos AR, Sen S. Effects of donor breastmilk feeding on growth and early neurodevelopmental outcomes in preterm infants: an observational study. *Clin Ther.* (2017) 39:1210–20. doi: 10.1016/j. clinthera.2017.05.341

53. Jacobi-Polishook T, Collins CT, Sullivan TR, Simmer K, Gillman MW, Gibson RA, et al. Human milk intake in preterm infants and neurodevelopment at 18 months corrected age. *Pediatr Res.* (2016) 80:486–92. doi: 10.1038/pr.2016.114

54. Hair AB, Patel AL, Kiechl-Kohlendorfer U, Kim JH, Schanler RJ, Hawthorne KM, et al. Neurodevelopmental outcomes of extremely preterm infants fed an exclusive human milk-based diet versus a mixed human milk + bovine milk-based diet: a multi-center study. *J Perinatol.* (2022) 42:1485–8. doi: 10.1038/s41372-022-01513-3

55. Feldman R, Eidelman AI. Direct and indirect effects of breast milk on the neurobehavioral and cognitive development of premature infants. *Dev Psychobiol.* (2003) 43:109–19. doi: 10.1002/dev.10126

56. Colacci M, Murthy K, DeRegnier RO, Khan JY, Robinson DT. Growth and development in extremely low birth weight infants after the introduction of exclusive human Milk feedings. *Am J Perinatol.* (2017) 34:130–7. doi: 10.1055/s-0036-1584520

57. Bier JA, Oliver T, Ferguson AE, Vohr BR. Human milk improves cognitive and motor development of premature infants during infancy. *J Hum Lact.* (2002) 18:361–7. doi: 10.1177/089033402237909

58. Li T, Zhang G, Li R, He S, Zhang F, Yan X, et al. Survival and morbidity in very preterm infants in Shenzhen: a multi-center study. *Front Pediatr.* (2023) 11:1298173. doi: 10.3389/fped.2023.1298173

59. Flensborg-Madsen T, Mortensen EL. Infant developmental milestones and adult intelligence: a 34-year follow-up. *Early Hum Dev.* (2015) 91:393–400. doi: 10.1016/j. earlhumdev.2015.04.006

60. Klaus M. Mother and infant: early emotional ties. *Pediatrics*. (1998) 102:1244–6. doi: 10.1542/peds.102.SE1.1244

61. Bystrova K, Ivanova V, Edhborg M, Matthiesen AS, Ransjo-Arvidson AB, Mukhamedrakhimov R, et al. Early contact versus separation: effects on mother-infant interaction one year later. *Birth*. (2009) 36:97–109. doi: 10.1111/j.1523-536X.2009.00307.x

62. Feldman R, Rosenthal Z, Eidelman AI. Maternal-preterm skin-to-skin contact enhances child physiologic organization and cognitive control across the first 10 years of life. *Biol Psychiatry*. (2014) 75:56–64. doi: 10.1016/j.biopsych.2013.08.012

63. Horta BL, de Sousa BA, de Mola CL. Breastfeeding and neurodevelopmental outcomes. *Curr Opin Clin Nutr Metab Care.* (2018) 21:174–8. doi: 10.1097/MCO.00000000000453

64. Perrella S, Gridneva Z, Lai CT, Stinson L, George A, Bilston-John S, et al. Human milk composition promotes optimal infant growth, development and health. *Semin Perinatol.* (2021) 45:151380. doi: 10.1016/j.semperi.2020.151380

65. Zielinska MA, Hamulka J, Grabowicz-Chądrzyńska I, Bryś J, Wesolowska AAssociation between Breastmilk LC PUFA. Carotenoids and psychomotor development of exclusively breastfed infants. *Int J Environ Res Public Health.* (2019) 16:1144. doi: 10.3390/ijerph16071144

66. Martinat M, Rossitto M, Di Miceli M, Laye S. Perinatal dietary polyunsaturated fatty acids in brain development, role in neurodevelopmental disorders. *Nutrients*. (2021) 13:1185. doi: 10.3390/nu13041185

67. Walker SP, Wachs TD, Gardner JM, Lozoff B, Wasserman GA, Pollitt E, et al. International child development steering G. Child development: risk factors for adverse outcomes in developing countries. *Lancet*. (2007) 369:145–57. doi: 10.1016/ S0140-6736(07)60076-2

68. Berger PK, Ong ML, Bode L, Belfort MB. Human Milk oligosaccharides and infant neurodevelopment: a narrative review. *Nutrients*. (2023) 15:719. doi: 10.3390/ nu15030719

69. Dimitroglou M, Iliodromiti Z, Christou E, Volaki P, Petropoulou C, Sokou R, et al. Human breast Milk: the key role in the maturation of immune, gastrointestinal and central nervous systems: a narrative review. *Diagnostics (Basel)*. (2022) 12:2208. doi: 10.3390/diagnostics12092208

70. Strobel NA, Adams C, McAullay DR, Edmond KM. Mother's own Milk compared with formula Milk for feeding preterm or low birth weight infants: systematic review and Meta-analysis. *Pediatrics*. (2022) 150:e2022057092D. doi: 10.1542/peds.2022-057092D

71. Quigley M, Embleton ND, McGuire W. Formula versus donor breast milk for feeding preterm or low birth weight infants. *Cochrane Database Syst Rev.* (2019) 7:CD002971. doi: 10.1002/14651858.CD002971.pub5

72. Brown JVE, Walsh V, McGuire W. Formula versus maternal breast milk for feeding preterm or low birth weight infants. *Cochrane Database Syst Rev.* (2019) 8:CD002972. doi: 10.1002/14651858.CD002972.pub3

73. Miller J, Tonkin E, Damarell RA, McPhee AJ, Suganuma M, Suganuma H, et al. A systematic review and Meta-analysis of human Milk feeding and morbidity in very low birth weight infants. *Nutrients.* (2018) 10:707. doi: 10.3390/nu10060707

74. Lechner BE, Vohr BR. Neurodevelopmental outcomes of preterm infants fed human Milk: a systematic review. *Clin Perinatol.* (2017) 44:69–83. doi: 10.1016/j. clp.2016.11.004

75. Biasini A, Monti F, Laguardia MC, Stella M, Marvulli L, Neri E. High protein intake in human/maternal milk fortification for </=1250 gr infants: intrahospital growth and neurodevelopmental outcome at two years. *Acta Biomed.* (2018) 88:470–6. doi: 10.23750/abm.v88i4.5316

76. Lucas A, Fewtrell MS, Morley R, Lucas PJ, Baker BA, Lister G, et al. Randomized outcome trial of human milk fortification and developmental outcome in preterm infants. *Am J Clin Nutr.* (1996) 64:142–51. doi: 10.1093/ajcn/64.2.142

77. Brinkis R, Albertsson-Wikland K, Tameliene R, Aldakauskiene I, Rimdeikiene I, Marmiene V, et al. Impact of early nutrient intake and first year growth on neurodevelopment of very low birth weight newborns. *Nutrients*. (2022) 14:3682. doi: 10.3390/nu14183682

78. Makrides M, Gibson RA, McPhee AJ, Collins CT, Davis PG, Doyle LW, et al. Neurodevelopmental outcomes of preterm infants fed high-dose docosahexaenoic acid: a randomized controlled trial. *JAMA*. (2009) 301:175–82. doi: 10.1001/jama.2008.945

79. Vohr BR, Poindexter BB, Dusick AM, McKinley LT, Higgins RD, Langer JC, et al. Persistent beneficial effects of breast milk ingested in the neonatal intensive care unit on outcomes of extremely low birth weight infants at 30 months of age. *Pediatrics*. (2007) 120:e953–9. doi: 10.1542/peds.2006-3227

80. O'Connor DL, Ewaschuk JB, Unger S. Human milk pasteurization: benefits and risks. Curr Opin Clin Nutr Metab Care. (2015) 18:269–75. doi: 10.1097/MCO.000000000000160

 Mitha A, Foix-L'Helias L, Arnaud C, Marret S, Vieux R, Aujard Y, et al. Neonatal infection and 5-year neurodevelopmental outcome of very preterm infants. *Pediatrics*. (2013) 132:e372–80. doi: 10.1542/peds.2012-3979